# Five Strategies: From -$16M to Break-Even to +$20M

*Redlands Health — strategy engagement | verified by a three-lens adversarial panel | 2026*

> **Baseline:** client-stated -$16M/yr operating loss (public IRS-990 FY2024 showed -$8.6M; planned to the harder number). Planning estimates throughout — not actuarial, legal, or investment advice.

## Contents

1. Executive Summary — Managing Partner Synthesis
2. The Ranking
3. Strategy 1: RedlandsOS — The AI-Native Lean Hospital
4. Strategy 2: Redlands Unbound 2.0 — Fix the Core, Share the Center
5. Strategy 3: Terracina, Priced to Contract + The Independent Alliance
6. Strategy 4: SilverPass — Earn the Right
7. Strategy 5: Mothership & Fleet 3.0 — Turnaround First, Buy Don't Build
8. Portfolio & Sequencing
9. The Tesla Answer
10. The National Vision
11. Board Decision Memo
12. Appendix A — Panel Verdicts
13. Appendix B — Method

---

# Five Strategies to +$20M — Managing Partner Synthesis

## The mandate and the method
The client asked for paths from a -$16M operating loss to breakeven and then +$20M/yr — a ~$36M swing, ~5 points of margin, top-decile for any community hospital — with the full option space open from DTC telemedicine to acute-care repositioning, and at least one genuine pull-away move. Nine strategies entered three rounds of adversarial panel review (financial realism, market/competitive realism, regulatory/execution); five survived, most only after being rebuilt to concede what the panels proved.

## The central finding
The five survivors are not five choices. They are **one turnaround counted five times** (every plan carries the same bed consolidation, ALOS correction, CDI/denials, supply-chain, and premium-labor content), **one Arrowhead ASC deal structured three ways** (the panel-verified fact that the surgeons already own AASC makes Strategy 5's buy-in recapitalization the only winnable form), **one senior-risk option designed twice** (Strategy 3's PHN lever and Strategy 4's Block B), and **one externalization idea in two vehicles** — all bidding for the same MOB sale-leaseback, the same receivables facility, the same donor base, and the same four-workstream management ceiling at a distressed hospital with a first-year CEO. The engagement's real deliverable is a deduplicated portfolio.

## The ranking (best risk-adjusted path to +$20M first)
1. **Independent Alliance + Terracina sleeve (B-)** — the only mandate-adjacent path: breakeven FY2029 on ops levers, base +$8-10M, corrected success +$13-18M by FY2033-34 on one honestly probability-tagged MA-risk lever (~40-50%). The coalition premise (CAMG, RYMG-fled-Optum, PHN, Arrowhead) is the best-verified asset in the file.
2. **Mothership & Fleet 3.0 (B)** — highest panel confidence, cleanest arithmetic, every failure mode degrades to a still-breakeven fallback; contributes the correct ASC deal structure and the portfolio's Gate Zero discipline; Phase III-A is the second gated engine (+$11M).
3. **RedlandsOS (B, as infrastructure)** — not a path to +$20M (ceiling +$0-6M) but the mandatory margin engine under everything, competition-proof and regulation-light; its audited scorecard is the externalization option, carried at zero.
4. **SilverPass (C+)** — passes all three lenses and owns the engagement's most valuable insight (internalized Part A — the structural economics every dead senior-risk company lacked), but as a program it is the portfolio double-counted with a $69-94M capital plan that cannot coexist; absorb its underwriting discipline, do not fund it.
5. **Redlands Unbound 2.0 (C-)** — honest but dominated; salvage the command center, the Title 22-compliant tele-sitting scope, and the co-op governance model as an externalization candidate; retire the rest.

## The funded portfolio
One ops engine (RedlandsOS spec, ~$15-17M net run-rate swing, one transformation office, CFO-audited benefits) + one physician chassis (friendly-PC/MSO/CIN, built once) + one ambulatory engine (Track-B recaps) + two options at zero (PHN MA risk, gated FY2030; playbook externalization, Year 3+). Capital: ~$40-45M external, each source counted once. Year 1 is capped at four workstreams by board covenant.

## The honest arc
Breakeven FY2029 (P50 FY2030) → +$8-12M by FY2031-33 (2-3% margin, top-quartile) → +$15-20M FY2034-36 **only if two of three gated engines pay** (~35-50%). Every faster claim died in panel.

## The Tesla answer
No single strategy pulls away; the stack does: AI-native cost structure × SB 351-protected independent alliance × hospital-anchored senior risk with internalized Part A. Optum legally cannot lead it, Kaiser structurally cannot join it, LLU economically cannot price it. The national replication of that chassis to 400+ money-losing independents is the genuine Tesla claim — carried as option value, funded only after the boring layers are audited.

## What kills it
The unread master trust indenture, the unpriced 2030 seismic obligation, benefit-realization theater, a broken no-bedside-cuts covenant, and workstream sprawl. Gate Zero exists to retire the first two before a dollar moves; the transformation office and the board covenant exist to prevent the last three.

---

# The Ranking

*Ordered by best risk-adjusted path to +$20M first. Full rationale below the table; panel verdicts in Appendix A.*

| Rank | Strategy | Risk grade |
|---|---|---|
| 1 | Terracina, Priced to Contract + The Independent Alliance (Strategy 3) | B- |
| 2 | Mothership & Fleet 3.0 — Turnaround First, Buy Don't Build (Strategy 5) | B |
| 3 | RedlandsOS — The AI-Native Lean Hospital (Strategy 1) | B (as mandatory infrastructure; not rated as a standalone path) |
| 4 | SilverPass: Earn the Right (Strategy 4) | C+ |
| 5 | Redlands Unbound 2.0: Fix the Core, Share the Center (Strategy 2) | C- |

### 1. Terracina, Priced to Contract + The Independent Alliance (Strategy 3) — B-

The only strategy whose base case (+$8-10M by FY2030-31) and gated success case (panel-corrected +$13-18M by FY2033-34) live in the same decade as the mandate. Breakeven FY2029 rides cost/yield levers that need no market permission, and the entire base-vs-success gap is honestly isolated in one probability-tagged lever (PHN MA global risk, ~40-50%). Its coalition assets are the best-verified facts in the whole engagement: CAMG founded anti-consolidation, RYMG demonstrably fled Optum, PHN physician-owned with Optum as the feared alternative, Steinmann already inside RCH. Conditions of approval: restate the MA margin split to the co-capitalized structure, adopt Strategy 5's Track-B structure for the Arrowhead ASC line, book recapture mid-range. This is the portfolio's demand engine and the closest thing to a mandate-answering path that survived three adversarial rounds.

### 2. Mothership & Fleet 3.0 — Turnaround First, Buy Don't Build (Strategy 5) — B

Highest panel confidence in the set (60/70/62), the only arithmetically clean bridge in its family, and the only plan where every market failure mode degrades to a still-breakeven fallback (turnaround core breaks even Year 3 standalone on Tranche 1 alone). Its committed ceiling (+$1-2M by Year 7) cannot answer the mandate, so it ranks below Strategy 3 as a path — but its Track-B buy-don't-build architecture is the correct legal and negotiating form of the Arrowhead deal that Strategies 3 and 4 both mis-structure, and Phase III-A (+$11M by Year 11-12) is the portfolio's second gated engine toward +$20M. Its Gate Zero discipline — master-trust-indenture read, seismic/AB 869 confirmation, unrestricted-cash verification — becomes the portfolio's Gate Zero, because those risks are existential to all five strategies.

### 3. RedlandsOS — The AI-Native Lean Hospital (Strategy 1) — B (as mandatory infrastructure; not rated as a standalone path)

Not a path to +$20M and says so (honest ceiling +$0-6M, corrected breakeven FY2030) — but the highest risk-adjusted dollars anywhere in the set: competition-proof (Optum/Kaiser/LLU cannot block RCH from cutting its own costs), regulation-light (no CPOM, no Knox-Keene, no change of control), and no customer has to switch anything. It is the margin engine every other strategy's unit economics silently assume, and its audited scorecard creates the licensing/equity option (Ensemble precedent, $1.2B for 51%) carried at zero. It ranks third only because the charge ranks paths to +$20M; in funding order it is first — it starts day one, under the single transformation office, absorbing the command-center concept and all duplicate restructuring content from Strategies 2, 3, 4, and 5, counted once.

### 4. SilverPass: Earn the Right (Strategy 4) — C+

The only strategy passing all three panel lenses, and the owner of the single most valuable strategic insight in the engagement: internalized Part A at ~50 cents marginal cost is the one structural economics every dead senior-risk company (Oak Street, Cano, CareMax, agilon) lacked, and RCH is verifiably the only non-Kaiser hospital in the corridor that can own it. But as a funded program it is the portfolio double-counted: Block A duplicates the turnaround, its $69-94M capital plan re-spends the same MOB/ABL/philanthropy dollars plus a $30M operator check that post-Cano operators may not write, and its corrected plan of record (+$2-4M by 2035, +$20M ~2040) is the slowest dollar in the set. Verdict: do not fund as a program; absorb its underwriting discipline (realized-V28 economics, DMHC 1300.49 concurrent filing, the pre-agreed banker-run affiliation trigger) into the portfolio's gated MA-risk option.

### 5. Redlands Unbound 2.0: Fix the Core, Share the Center (Strategy 2) — C-

The most honestly-architected of the five, and still dominated on every axis. Its ops content is a shallower copy of RedlandsOS; its only income-positive layer (the co-op) prices to roughly $0-1M once held to the verified Avel comp; $14M of its $22M capital is uncommitted philanthropy/PRI sized 3-5x market norms with no anchor; and both market panels scored it NOT viable. Salvage exactly three components: the 24/7 command-center operating concept (folds into RedlandsOS), the Title 22 CCR 70217-compliant tele-sitting scope (the legally correct version of virtual nursing in California), and the member-owned co-op governance model as one of two candidate vehicles for the Year-3+ externalization option. Retire the rest.

---

*Strategy 1 of 5 — inserted as submitted; panel verdicts in Appendix A.*

# Strategy: RedlandsOS — The AI-Native Lean Hospital

**Archetype: the margin engine.** Four of the five strategies in this report argue about where RCH's next dollar of revenue comes from. This one argues about what happens to every dollar RCH already has — and it is the only strategy that must be true no matter which growth path the board picks.

## The situation: a 2005 operating model on a 2026 cost structure

RCH spends $415.7M a year (IRS-990 FY2024) to produce declining volume, and the operational fingerprints of the -$16M loss are visible in its own filings. Average length of stay has drifted from 3.5 days (2018) to 4.5 days (2024) — on 9,604 discharges, each 0.1 day is roughly 960 patient days of cost. The hospital almost certainly runs at or near the industry's ~11.6-11.8% initial denial rate, part of a national problem that cost providers [$48.4B in leaked net revenue in 2025](https://www.experian.com/blogs/healthcare/healthcare-claim-denials-statistics-state-of-claims-report/). Coding is human-only, staffing gaps are plugged with registry premiums, prior auth and HIM still run on phone and fax, and the back office is sized for the paper era. None of this is a criticism of the people doing the work; it is a description of the operating model they were given.

The evidence that AI fixes exactly this defect list — at community-hospital scale, not just academic-center scale — is now documented, not promotional. [Auburn Community Hospital](https://www.aha.org/aha-center-health-innovation-market-scan/2024-06-04-3-ways-ai-can-improve-revenue-cycle-management), a 99-bed independent, posted a 4.6% case-mix-index increase, a 50% cut in discharged-not-final-billed, and 40%+ coder productivity gains. [Jackson Health cut mean excess days 0.42 for $6.7M annualized](https://www.qventus.com/company/newsroom/qventus-drives-next-wave-of-healthcare-ai-innovation-with-debut-of-ai-solution-factory-and-releases-new-roi-outcomes-from-health-systems/); Qventus clients typically eliminate 15-30% of excess days. Predictive staffing has [cut contract-labor dependence 15% within six months](https://www.varshealth.com/post/hospital-staffing-ai-how-ai-driven-workforce-management-is-replacing-agency-chaos-in-2026), and [UCSF cut backorders 70%](https://www.chooch.com/blog/how-ai-is-revolutionizing-hospital-supply-chain-management/) with AI supply-chain forecasting. Ambient documentation — now adopted by [62.6% of Epic hospitals](https://www.ajmc.com/view/ambient-ai-tool-adoption-in-us-hospitals-and-associated-factors) — rounds out the stack, though under California CPOM most physician-productivity gains accrue to the independent groups, so we size it honestly small.

**One covenant governs everything: no cuts to bedside clinical staff.** All labor capture comes from registry elimination, managed attrition in non-clinical roles, and contract exits. This is both an ethical position and cold strategy — the CIN and employer plays depend on clinician and community trust that a layoff-led program would destroy.

## The financial bridge (steady state, FY2031)

| Lever | $M/yr | Basis |
|---|---|---|
| Baseline operating loss | -16.0 | Client-stated run rate (990 FY2024: -$8.6M) |
| CDI/CMI uplift (est) | +3.2 | ~2.5% on ~$130M DRG-paid IP revenue (Auburn: +4.6%) |
| Denials prevention + recovery (est) | +3.4 | ~0.85 pts of write-off on ~$400M NPR |
| Autonomous coding / rev-cycle cost (est) | +3.5 | ~40% of est $9M coding/billing labor, attrition-paced |
| Patient flow — excess days + backfill (est) | +3.0 | -0.45 ALOS x 9,604 disch. at non-labor variable + OR backfill |
| AI staffing + float pool (est) | +5.9 | ~45% of est $13M registry/OT/premium spend |
| Agentic back office + app rationalization (est) | +3.2 | ~9% of est $35M admin labor/purchased services |
| AI supply chain (est) | +2.4 | ~4.4% of est $55M supplies/drugs |
| Energy/facilities AI (est) | +0.7 | ~15% of est $4.5M utilities |
| Ambient — throughput/retention net (est) | +1.3 | Sized small; CPOM routes most gains to independents |
| RedlandsOS licensing net (est) | +2.0 | 12-15 hospitals x ~$300-400k x ~45% margin, Yr 5 |
| NEW: platform/compute/cyber | -4.6 | Run-rate stack, net of at-risk structures |
| NEW: transformation office (16 FTE) | -3.0 | CAIO + engineers/informaticists/analysts |
| NEW: depreciation + change mgmt | -1.7 | ~$12M capitalizable build / 7 yrs |
| **Steady-state operating income** | **+3.3** | **~0.8% margin** |

Anti-double-count discipline: the flow lever is monetized at *non-labor* variable cost only; all labor flex from lower census flows through the staffing lever. Ramp: -$12M (FY2027), -$4M (FY2028), **breakeven FY2029**, +$2M (FY2030), +$3.3M (FY2031).

**And the honest ceiling, stated plainly: this strategy alone does not reach +$20M.** A +$36M ops-only swing means stripping ~9% of the expense base net — two to three times the best documented system-wide results — without touching care. It does not exist. What this delivers is the entire journey from -$16M to a [median-margin hospital (Kaufman Hall: 1.3% median, CY2025)](https://www.kaufmanhall.com/insights/research-report/national-hospital-flash-report-december-2025-data), plus the cost structure that makes every growth strategy's economics work: the ASC/employer strategies inherit clean rev-cycle; the Pass strategy inherits the staffing model; the CIN inherits ambient-equipped, loyal independents.

## Capital: $28M, none of it from the balance sheet

$18M build + $10M ramp coverage, sourced externally: **vendor at-risk contracts** (~$4-5M equivalent — flow/staffing vendors routinely put 30-50% of fees at risk against verified savings); an **$8-10M philanthropy campaign** — "the first AI-native community hospital in America" is a fundable identity for Redlands' ESRI-adjacent tech wealth in a way that deficit-plugging never is; **$8-12M sponsor equity into the RedlandsOS NewCo**, where the investor funds productization and RCH contributes playbook IP for founder equity — the [Ensemble Health Partners precedent (Bon Secours Mercy's RCM unit; 51% sold for $1.2B)](https://www.beckershospitalreview.com/finance/bon-secours-mercy-health-to-sell-majority-stake-in-ensemble-to-golden-gate-capital/) shows a hospital-born services company can become worth more than the hospital's decade of operating income; and **$4-6M IT financing** on the capitalizable build.

## Operator's plan: first hires, first deals, first 12 months

**First five hires:** (1) Chief Transformation & AI Officer — an operator who has deployed at hospital scale, reporting to the CEO; (2) VP Revenue Intelligence, owning the CDI/coding/denials P&L; (3) Principal Healthcare Data Engineer, building the EHR-to-lakehouse data spine; (4) Director of Clinical Informatics — a nurse informaticist with bedside credibility to carry the flow and staffing tools; (5) (Year 2) GM of RedlandsOS, from the RCM/MSO services world. **First three deals:** an at-risk patient-flow + staffing contract (Qventus/LeanTaaS-class, ≥50% contingent); an autonomous coding + denials platform priced on verified incremental collections (CodaMetrix/Nym/AKASA-class); an enterprise ambient deal covering hospitalist/ED providers **with a subsidized extension to CAMG and RYMG** — adoption glue that doubles as CIN recruiting currency. **First 12 months:** Q1 — CAIO hired, denial taxonomy and excess-day audits, registry-spend baseline, vendor selection; Q2 — denials prevention live, flow AI in med-surg and ED boarding; Q3 — staffing AI + internal float pool, ambient go-live; Q4 — autonomous coding phase 1 (ED/radiology/pathology first), supply-chain forecasting, and publication of a third-party-audited Year-1 scorecard targeting a +$6-8M annualized run-rate swing. That scorecard is not PR — it is the founding asset of RedlandsOS.

## The moat, honestly

Software is not a moat; Kaiser, LLU, and Optum will run their own versions, and Optum sells one. The defensible seat is narrower: RCH as the **not-payer-owned, not-PE-owned, SB351-clean reference implementation** for 400+ money-losing independents who structurally distrust Optum — the vendor category they are fleeing — plus three years of audited, community-scale execution data no vendor ships. A copycat can buy the same stack in three years; it cannot buy the track record. And if the moat fails entirely, the internal P&L case still stands at zero licensing revenue.

## Risks that keep us honest

(1) Announced-vs-audited savings — every dollar needs CFO-signed benefit realization; (2) baseline decay (-6%/yr discharges) can outrun capture — pair with a growth strategy, mandatory; (3) attrition may not open where automation lands; (4) vendor consolidation/pricing power; (5) thin change capacity under a new CEO; (6) RedlandsOS is an option, not a plan — modeled at only +$2M.

## The national picture

America's default answer to failing community hospitals is absorption — consolidation with documented price increases and closed service lines. RedlandsOS is the counter-proof: an independent 211-bed hospital moving from -4% to median margin through productivity instead of market power or rationing, then handing the blueprint to every independent board that tours the building. A top-tier nation does not need fewer hospitals; it needs hospitals that spend on care instead of denials rework, fax queues, and agency premiums. That model, licensed at scale, is how one hospital in Redlands moves the national number.

---

*Strategy 2 of 5 — inserted as submitted; panel verdicts in Appendix A.*

# Redlands Unbound 2.0: Fix the Core, Share the Center

*Archetype: decentralized hospital / shared command-center utility. Status: repaired and resubmitted after adversarial review.*

## What changed after review

The panel found three fatal flaw classes. This revision concedes all three rather than re-arguing them.

**1. The B2B economics were fantasy at the stated price.** The original plan needed ~$2.05M per site from distressed hospitals; its own precedent — Avel eCare, $92M FY24 revenue across 1,200+ sites — implies ~$77-150k per site. The book is repriced to evidence: comprehensive small-hospital bundles at $300-800k, modular services at $75-150k, per-episode terms so cash-constrained buyers can sign. The buyer pool is rebuilt around credit-qualified purchasers — tax-levying California healthcare districts, stable small systems, out-of-state critical-access hospitals — not insolvent prospects like San Gorgonio (Ba2, failed bridge financing), which is now a Wave-2 possibility at per-episode pricing, not the flagship. Three or more signed LOIs at modeled pricing are a precondition to co-op capital. The panel's recomputation also caught an $8M double-count (+$7-9M "base plateau" restated after overhead had already consumed it); the bridge below nets contribution and overhead exactly once.

**2. California hospital-at-home is not operable today.** CDPH program flexibilities expired February 28, 2023; CHA says state action is needed; CNA has kept every enabling bill dead. Every HaH-dependent dollar is therefore removed from the planning case, which also assumes the AHCAH waiver sunsets September 30, 2030 with no reauthorization. Bed consolidation is re-founded on census math alone. Home-based care survives only in non-GACH modalities (SNF-at-home, post-acute, ED-to-home observation under MA and commercial episode contracts). The first co-op cohort sells in AHCAH-operable states (AZ/NV/TX). CA HaH becomes Gate 0: a written CDPH position, a funded CHA/Moving Health Home advocacy lane, and a pre-built pivot — upside only.

**3. The capital structure contradicted the moat and would not clear a sponsor IC.** The PE-sponsored NewCo — which negated the "fellow NFP" trust story and demanded a $73-89M post-money on a pre-revenue entity — is replaced by a member-owned NFP cooperative funded by philanthropy, program-related investments, member subscriptions, and equipment leases ($22M staged vs. $48M). The unsupported "waiver track record" claim is dropped. Growth equity survives only as a proof-gated Year 5+ option under an SB 351-compliant governance charter. The full legal stack is now drawn: Moscone-Knox friendly PC + RCH MSO to bill RPM/CCM and hold attributed lives under CPOM; AB 1415 90-day OHCA notice with a 6-9 month CMIR contingency; a Corporations Code 5914-5925 counsel opinion before any asset contribution; transfer pricing at documented FMV, invariant to referral volume, with annual AKS/Stark audit.

**And the honest headline:** this strategy cannot deliver +$20M, and it no longer claims to. Planning case: core breakeven run-rate in Year 4, consolidated +$1-2M by Year 6; roughly +$5M by Year 7-8 if the conditional layers land. Its portfolio role is the foundation layer — it makes the core self-sustaining on non-dilutive external capital, de-risks every other chapter, and creates the co-op replication option. The Tesla mandate must be carried elsewhere in this portfolio.

## Situation

RCH runs 211 licensed beds at 56.6% occupancy — an average daily census of ~119 — with discharges down 31% since 2018 (13,946 to 9,604) while ALOS drifted from 3.5 to 4.5 days. The loss is -$16M on ~$407M revenue against a $415.7M expense base. The ED remains a genuine front door (61,472 visits), but ~63% of core inpatient demand leaks and ~70% of that leak is structurally locked. The building is sized for a hospital that no longer exists, and the cost structure never followed the volume down. The arithmetic conclusion: the fix must come principally from cost structure, flow, and revenue integrity — not heroic growth — and any growth story must be priced to comps, not hope.

## The model: three concentric rings

**Ring 1 — run the hospital from a command center (Years 1-3).** A 24/7 operations center drives the demand-independent levers: tele-sitting and virtual documentation (scoped to what Title 22 ratio law actually allows), ALOS correction back toward 4.0, CDI and denial prevention, supply-chain and purchased-services capture, and consolidation to ~175 staffed beds justified by census alone. These ten levers gross +$21.75M and none of them require a waiver, a statute, or a partner.

**Ring 2 — the clinical network (Years 2-5).** A friendly-PC + MSO stack makes RPM/CCM billable and holds attributed lives for employer/payer shared savings at Knox-Keene rung 1. A transfer/access center keeps ~330 community-acuity transfers partners genuinely cannot serve — FMV-priced, partner-directed, renewal-durable. Non-GACH home-based episodes run under MA/commercial contracts gated at cost-plus-15%.

**Ring 3 — the cooperative (Years 3-7).** "Inland Health Cooperative": member-owned, open-book, cost-plus. Members buy virtual nursing, tele-sitting, flow management, transfer coordination, and (out of state) HaH enablement at $300-800k comprehensive or per-episode. Launch is quality-gated — CMS 3+ stars and 12-18 months of documented internal results before the first outside sale, because the reference product is the product.

## The bridge (planning case: no CA HaH, AHCAH sunsets 2030)

| Lever | $M/yr | Timing |
|---|---|---|
| Workforce virtualization (Title 22-rebased) | +1.25 | Yr1-2 |
| Command-center flow: ALOS + LWBS | +2.00 | Yr1-3 |
| Revenue integrity: CDI + denial prevention | +2.00 | Yr1-3 |
| Supply chain + purchased services + vendor consolidation | +3.50 | Yr1-3 |
| Staffed-bed consolidation to ~175 (census-founded) | +4.00 | Yr2-3 |
| Home-based care, non-GACH modalities | +1.50 | Yr2-4 |
| Transfer/access-center keepage (FMV, re-founded) | +1.50 | Yr3-5 |
| Quality-gated share recapture | +2.00 | Yr3-5 |
| RPM/CCM via friendly PC + MSO | +1.00 | Yr3-5 |
| Employer/payer shared savings (rung 1) | +1.00 | Yr4-6 |
| Co-op services, 12-15 members at Avel-comp pricing | +2.00 | Yr3-6 |
| Command-center core overhead (new) | -1.75 | Yr1 on |
| Co-op growth organization (~13% of services revenue) | -1.00 | Yr3 on |
| Depreciation (~$8.5M capitalized, 5-7 yr lives) | -1.25 | Yr1 on |
| Friendly-PC/MSO net operating cost | -0.50 | Yr2 on |
| **Net swing (planning case)** | **+17.25** | |
| **Consolidated at Year 6 (from -$16M)** | **+$1.25M** | |

Trajectory: Year 1 ~-$15.8M, Year 2 ~-$10.4M, Year 3 ~-$5.5M, Year 4 ~-$2M (core run-rate crosses zero), Year 5 ~+$0.5M, Year 6 +$1-2M. Conditional layers, excluded above: CA HaH enablement plus AHCAH reauthorization (+$2.0M via a payer-mix funnel of ~370 Medicare FFS episodes) and co-op Wave 2 to 25-30 members (+$1.75M) take the ceiling to roughly +$5M by Year 7-8. Each dollar states its basis; transfer keepage and recapture together use ~28% of the re-underwritten 2,500-3,100 winnable pool, deduplicated.

## Capital: $22M, staged and gated

Tranche A ($9M, Year 1): command-center fit-out, monitoring equipment, CDI program, PC/MSO formation — philanthropy $4M, equipment leases $3M, PRIs $2M. Tranche B ($7M, Years 2-3): home-care fleet, RPM, working capital — PRIs $4M, philanthropy $2M, member prepaids $1M. Tranche C ($6M, Years 3-4, released only on 3+ signed LOIs, 3+ stars, and 12-18 months of internal results): co-op productization and J-curve working capital — member subscriptions $3M, PRIs $2M, growth debt $1M. Peak cumulative cash need ~$18M, modeled year-by-year, with ~$4M contingency. Donors fund a tangible keep-care-local asset; foundations fund replicable sustainability infrastructure repaid from documented savings; members buy in because cost-plus beats market. The residual Alquist obligation on the retained footprint — estimated $30-50M — is named, held outside this raise, and pursued via statutory extension and post-turnaround Cal-Mortgage-insured debt.

## Moat — the honest version

The identity moat is dropped; Avel's post-PE growth disproved it. What survives three years of attack: ownership economics (for-profit vendors cannot sell at cost-plus without dismantling their model; Optum/Kaiser/LLU cannot offer board seats to hospitals that fear them), the physical last mile in the Inland Empire, and FMV transfer relationships built to survive renewal diligence. Stated limits: commodity technology, module-level price competition, Kaiser serving its own members, and a waiver window shared with 373 hospitals. This is a defensible niche, not a Tesla lead.

## Risks

CA HaH stays closed (already the planning assumption); CNA bargaining delays the bed and sitting levers 6-12 months; the quality gate fails and Tranche C never releases (strategy reverts to a breakeven core fix); co-op demand proves thinner than screened; OHCA/CMIR and AG review stretch the co-op timeline; execution bandwidth at a 2-star hospital (capped at 2-3 concurrent hospital-side workstreams; the co-op hires its own management); the seismic overhang remains a named, unfunded enterprise item; co-op structure trades equity upside for trust; philanthropy/PRI commitments must anchor before ground breaks.

## National vision

The analog is the rural electric cooperative: the country electrified farm country by letting members own the infrastructure and share it at cost. Hundreds of small American hospitals face RCH's exact math. A member-owned command-center utility — governance and shared fixed cost, not proprietary technology — is replicable by any state hospital association. If the Inland Empire pilot works, the national payoff is not a margin line; it is keeping community acute care alive at a cost per case the system can actually bear. That is the infrastructure layer of a top-tier nation, and it is worth building even though — stated plainly one last time — it is a +$1-5M strategy with an option attached, not a +$20M engine.

---

*Strategy 3 of 5 — inserted as submitted; panel verdicts in Appendix A.*

# Terracina, Priced to Contract — The Escalation Sleeve + The Independent Alliance, One Motion

**One line:** The consumer-health sleeve survives adversarial review only at honest scale — +$0.4M net booked, a +$1-2M ceiling, $2M of contract-gated capital — so it is resubmitted as one board motion with its pairing now named and underwritten: The Independent Alliance, whose combined bridge reaches breakeven in FY2029 and +$20M by FY2033-34 only if one gated, probability-tagged lever matures.

## What changed after review

The panel verified three market facts against the original sleeve, and this revision concedes all three instead of re-asserting. (1) Function/Ezra already ships the $499 full-body MRI through ~100 RadNet/SimonMed partner sites — so the scan line is re-priced off the buyer's retail anchor (~$260 blended contribution, ~1,500 studies sized from platform member density, not scanner headroom: $0.4M, inside the panel's own $0.3-0.6M range) and carries zero capex until 2+ signed multi-year minimums cover 60%+ of volume. (2) Quest (Function's national lab partner, with Redlands coverage) plus the Getlabs acquisition zero the lab-draw line — deleted, not haircut. (3) The DEA extended telehealth flexibilities a fourth time through 12/31/2026 with a no-in-person permanent pathway proposed — the hormone line goes to $0 as a dated option, and LLU's active GLP-1 and Executive Health programs mean the executive-assessment product is conceded outright. Further: the consumer membership is killed (a 2-star brand cannot price $420 above Function's $365 national offer); Phase 2 orchestration is killed (RadNet is the orchestration layer); downstream episodes are haircut by RCH's own 36.8% keep-rate (~220 episodes, $0.5M); sale-leaseback rent (-$1.0M/yr) is booked as the permanent drag it is; platform prepayments are removed as capital; the AG 5914/5920 workstream moves into Phase 1 where the sale-leaseback actually sits, with the AR facility sequenced first; RIF savings are booked at 70% capture behind a Cal-WARN/labor plan; advertising savings at 80% pending GL verification; the timeline slips 12-18 months on all platform lines (sleeve cash-positive FY29). And the panel's largest objection — that the pairing this sleeve depends on was named-but-absent — is answered by making the pairing the submission.

## Situation

RCH loses $16M a year on $407M of revenue with a balance sheet that cannot fund its own repair. The re-underwritten facts are unforgiving: only 2,500-3,100 leaked discharges are winnable; the longevity consumer belongs to Function nationally and LLU locally; squeezing a 1-3%-margin core cannot produce a 5-point swing. But two assets survived every round of adversarial review: a genuinely scarce physical escalation layer (the only independent full-stack CLIA-lab/imaging/OR/admitting counterparty between Los Angeles and Palm Springs), and a once-in-a-generation alignment window — 38+ verified independent physician groups, PHN IPA's ~54k lives, Arrowhead Orthopaedics' 27+ surgeons — in a market where the alternative is Optum, and where SB351 excludes hospitals from the PE restrictions that bind every other consolidator.

## The model: two sheets, one motion

**Sheet 1 — the Escalation Sleeve (repaired Terracina).** RCH sells wholesale clinical fulfillment to consumer-health platforms: imaging slots priced off the $499 retail anchor, and the one thing imaging chains structurally cannot offer — a managed finding-to-workup-to-procedure-to-admission pathway for the incidental findings that are the platforms' biggest clinical liability. Contract-first: $2M staged capital, 2 FTE, $0 of refit until signatures. If platforms will not sign against their incumbent RadNet network, the sleeve dies in 12 months at under $0.5M sunk — that outcome is a cheap, informative experiment, not a failure of the portfolio.

**Sheet 2 — The Independent Alliance (the named pairing).** A CIN/MSO built on the Tier-1 anchors (CAMG, RYMG, Maren, PHN — a realistic first-wave panel of 80-150k lives per the provider census), an ortho/spine ASC JV with Arrowhead, employer-direct occ-health and COE bundles with the 12 in-city self-funded employers, hospice and hospital-at-home expansion, a gated Pass-corridor beachhead — and, behind an FY2030 performance gate, MA global risk co-capitalized with PHN. Underneath both sheets: $15.2M of strategy-agnostic restructuring (beds, advertising, non-labor cost, revenue integrity, ED yield, gated 340B), counted once.

## The bridge (steady-state, success case at gates; $M from -16.0)

| # | Lever | $M | Basis (all est) | Timing |
|---|---|---:|---|---|
| 1 | Bed consolidation 211→~160 | +4.5 | ~120 FTE x $110k, $6.5M model x 70% capture; Cal-WARN plan first | FY27-28 |
| 2 | Exit brand advertising | +1.2 | 80% of $1.5M claim, pending GL/990 verification | FY27 |
| 3 | Non-labor cost program | +5.0 | ~1.2% of $416M opex (benchmark 1-2%) | FY27-29 |
| 4 | Revenue integrity | +3.0 | ~0.75% of $407M NPR (leakage 1-3%) | FY27-28 |
| 5 | ED front-door yield | +1.5 | ~900 LWBS x $600 + status accuracy on ~14k admits | FY28 |
| 6 | 340B (gated on DSH verification) | +2.0 | Contract-pharmacy expansion; booked post-eligibility only | FY28-29 |
| 7 | CIN-driven recapture to 41-42% | +4.5 | ~3,000 winnable discharges x ~$1,500 contribution | FY29-31 |
| 8 | ASC JV w/ Arrowhead (51%) | +1.5 | 51% of ~$3.5M JV EBITDA, net of HOPD cannibalization | FY29-30 |
| 9 | MSO fees | +1.5 | ~150 providers x ~$10k EBITDA (Privia 15-20%) | FY30-31 |
| 10 | Employer direct (merged, pilot-gated) | +1.2 | ~2,000 encounters/bundles x ~$600 blended; no exec health | FY28-29 |
| 11 | Hospice/palliative | +1.0 | ~50 ADC x 365 x $220 x ~30% incremental contribution | FY28-30 |
| 12 | Pass corridor (gated) | +2.0 | ~$8-10M revenue x 20-25% EBITDA benchmark | FY31-32 |
| 13 | Hospital-at-home | +1.0 | ~9 ADC x ~25% cost delta, net of program cost | FY29-30 |
| 14 | MA risk w/ PHN (gated FY30) | +9.7 | 16-18k lives x ~$13.5k x 4-4.5% net of risk-ops; ~40-50% prob. | FY33-34 |
| 15 | Sleeve: scan fulfillment (contract-gated) | +0.4 | ~1,500 studies x ~$260 off $499 retail anchor | FY29 |
| 16 | Sleeve: downstream episodes | +0.5 | ~600 findings x 36.8% keep x $2,300 | FY29-30 |
| 17 | Venture BD/compliance office | -0.5 | 2 FTE + DMHC/AKS/UBIT/655.5 counsel file | FY27+ |
| 18 | Quality turnaround (stroke accelerated) | -1.5 | Stroke fix FY27; balance 12mo post-RIF; philanthropy offsets | FY27+ |
| 19 | Sale-leaseback rent | -1.0 | ~8% cap on ~$12M proceeds — booked permanently | FY28+ |
| 20 | Alliance operating overhead | -1.5 | CIN/MSO/care-management infrastructure | FY28+ |
| | **Net swing** | **+36.0** | **-16.0 → +20.0 success case; +$8-10M base case** | |

No double-counting: employer lives are excluded from sleeve lines; sleeve downstream excludes ED-leakage recapture; ED yield is throughput, not share; restructuring is counted once portfolio-wide. Trajectory: -$11M FY27, -$4.5M FY28, breakeven FY29, +$4-6M FY30, +$8-10M base plateau FY31-32, +$20M FY33-34 only if line 14 matures.

## Capital

$14-16M staged program capital plus a $15M AR-backed liquidity facility, counted once: the facility is sequenced first (so Year-1 survival never waits on the AG); the ~$12M sale-leaseback runs through a budgeted 4-6-month Corp. Code 5914/5920 review in Phase 1 — the panel's identified error, fixed — and funds the ASC equity ($4M), the contract-gated sleeve ($2M), and ~$6M of liquidity against ~$16M of cumulative FY27-29 deficits; Arrowhead co-invests 49% in the ASC; PHN co-capitalizes the gated risk entity; the $7M Next Century campaign is ring-fenced to quality and seismic planning and never touches for-profit exposure. Prepayments are upside, not funding.

## Moat, honestly

The sleeve's moat is a supplier moat: real (only full-stack independent counterparty in the corridor; only a hospital closes the incidental-finding loop) but narrow, and worthless if platforms stay with RadNet — hence contract-first. The portfolio's moat is the one that matters: a coalition Kaiser cannot copy (closed by design), Optum cannot lead (it is what the independents are fleeing, and SB351's hospital exclusion lets RCH offer what PE legally cannot), and LLU cannot price (academic cost structure, tertiary focus). It is Southwest's moat, not Tesla's — durable 3-5 years, defended by speed and contracts — and we say so.

## Risks

The +$20M case rests on one named lever (MA risk, ~40-50%, capped J-curve exposure $3-4M); the sleeve may die cheaply; the AG may condition the sale-leaseback; RIF capture may miss; Optum may buy the anchors one by one; LLU may counter in employer contracting; and a distressed hospital with a first-year CEO must not run more than the 4-5 gated Year-1 workstreams this plan allows. Each carries a stated mitigation, and the board approves the two sheets as a single motion — the pairing is enforced by resolution, not hoped for.

## National vision

If an independent 211-bed hospital can restructure its core to real demand, federate its region's independent physicians without buying them, migrate care to honest-economics settings, graduate to premium risk behind gates, and sell its scarce physical layer wholesale to the consumer-health wave — against Optum, Kaiser, and an academic giant — then the roughly 900 American community hospitals in RCH's position have a blueprint that is neither absorption nor decline. That pattern, replicated, keeps physicians independent, moves care to lower-cost settings, gives DTC health a managed clinical back-end, and does more for national outcomes than another decade of vertical consolidation.

---

*Strategy 4 of 5 — inserted as submitted; panel verdicts in Appendix A.*

# SilverPass: Earn the Right

## Restructure-first senior risk — rebuilt after second adversarial review

**What changed after review.** The panel's core findings are accepted, not argued with. (1) The architecture is inverted: the restructuring is now the plan of record and reaches break-even with zero value-based-care contribution; the risk book is a severable, partner-funded option behind signed gates. (2) The turnaround is deepened from 1.6% to 2.4% of the expense base — mid-range of the 2-4% distressed benchmark the panel itself cited — and an ortho/spine ASC JV (RCH's #1-scored service line) is added so the firm plan breaks even alone. (3) The risk book shrinks from 3 centers/7,200 all-payer lives to 2 centers/4,000 MA-attributed lives, sized against the 7.5-8.5k contestable non-Kaiser MA pool, with an attribution audit and a RYMG equity term sheet as launch pre-conditions. (4) Economics are rebased to realized V28: $1,700/patient center contribution, platform repriced to market 6.5% of premium, CAC at $4,000/life, hospice at RCH share, stop-loss on both books, and a -$0.7M retained-governance line — resolving the 10.4%-vs-4-5% margin inconsistency at 4.7% enterprise take. (5) SGMH/the Pass is re-underwritten to $0 (LLU's 2015 incumbency acknowledged); engagement starts 2026-27, partner-led. (6) The DMHC instrument is corrected to a 1300.49 exemption application filed concurrently with a Restricted Knox-Keene application. (7) Capital is restructured to survive diligence: a distribution waterfall (80/20 until 1x return, then 51/49), binding FMV fee schedule, and a $5M development-rights fee bolstering hospital liquidity. (8) The 340B/DSH interaction is a decision gate before OB closure. (9) Concurrent majors are capped at four per wave. (10) The ask is restated honestly: fund a break-even restructuring plus an option; the central case is +$6.1M by 2035, and +$20M is disclosed as un-underwritten option value.

## Situation

RCH loses $16M a year on $407M of revenue. Discharges are down 31% since 2018, births down 38%, occupancy sits at 56.6%, and 63% of the core inpatient market leaks — roughly 70% of it structurally locked to Kaiser, LLU, and Arrowhead tertiary care. Squeezing a 1-3%-margin core cannot produce a $36M swing, and the prior review proved that no honest underwriting of senior risk can either — not on the mandate clock. What RCH does hold: the only non-Kaiser acute beds in its corridor, the region's best independent surgical franchise (ortho/spine, US News High Performing x4, Arrowhead's 27+ surgeons), a lockable independent physician base racing away from Optum, and a balance sheet that can fund none of it.

## The model

**Block A — Earn the right (2026-2030).** Four hospital-side majors in Wave 1: a contingency-fee turnaround at distressed depth; the Cortese SB 1300 OB process, gated on a Phase-0 340B/DSH model (post-closure DSH ≥ 13% or OB stays); CMS 3-star and stroke-mortality remediation; and the MOB sale-leaseback. Wave 2 adds delicensing to ~160 beds with seismic rescope and the ASC JV — built in a delicensed wing RCH contributes as its 40% equity, with Arrowhead and an ASC operator funding the fit-out. Standalone break-even lands in 2030 (substantively 2029, ±$1M) with no dollars from risk.

**Block B — Exercise the option (2029-2035).** Two dense senior clinics on 4,000 MA-attributed lives converted with their physicians (RYMG/CAMG/Rancho Paseo hold NewCo equity, not unenforceable exclusivity), plus hospital-held institutional-only capitation on 6,000 in-footprint PHN lives after a DMHC determination. Underwritten at realized V28 economics with the MLR bridge published: premium $1,075 PMPM; claims including internal Part A at transfer price ~74%; clinic cost-of-care ~$137 PMPM; center contribution $1,704/patient; then market-rate platform fee (6.5%), stop-loss, and churn CAC. The book nets 2.6% of premium; the internalized-Part-A hospital shift adds 2.1%; 4.7% enterprise take sits inside the 3-6% benchmark — earned by the one structural asset every dead senior-risk company lacked.

## The bridge

| Tier | Lever | $M/yr | Basis (all est) | Timing |
|---|---|---|---|---|
| FIRM | Operational turnaround | +10.0 | 2.4% of $415.7M expenses; benchmark 2-4% | full 2029 |
| FIRM | Right-sizing to ~160 beds | +2.5 | $1.2M opex + 3,842 bed-days × $350 | 2027-29 |
| FIRM | OB consolidation (340B/DSH-gated) | +2.0 | Fixed cost at 1,336 births; deleted if gates fail | 2028 |
| FIRM | Ortho/spine ASC JV (40%) | +1.2 | $13.5M rev × 28% EBITDA × 40% − cannibalization | 2029-31 |
| FIRM | Recapture byproduct | +2.5 | Ceiling $2-5.5M; below midpoint | 2029-31 |
| FIRM | MOB rent | -1.0 | 8.5% NNN on $12M | 2027+ |
| FIRM | Clinic book NET (4,000 lives) | +1.3 | 2.6% of $51.6M premium; $1,700/pt realized V28 | 2029-34 |
| FIRM | Hospital shift, clinic book | +1.1 | $3.65M managed − $2.53M baseline | 2034 |
| FIRM | Institutional cap NET (6,000 lives) | +1.0 | $34.6M pool × 3.0%; DMHC-gated | 2029-33 |
| FIRM | Hospital shift, institutional | +1.7 | $5.8M managed − $3.8M baseline, ramped | 2031-34 |
| FIRM | Hospice/HH JV, RCH share | +0.5 | 51% × 13.5% × $8M | 2031-34 |
| FIRM | Retained risk governance (SB 351) | -0.7 | Non-delegable PC/RCH functions | 2029+ |
| **FIRM subtotal** | | **+22.1** | **= +$6.1M consolidated OI** | **~2035** |
| GATED | Pass via SGMH (booked $0) | +3.1 | Won district process vs LLU + capitated bed-days | 2032-37 |
| GATED | IEHP D-SNP duals | +2.9 | LOI + MLR ×4 qtrs + 3-star | 2033-38 |
| GATED | Corridor densification | +1.2 | +2,000 lives if attribution supports | 2033+ |
| GATED | Interventional cardiology | +1.8 | Cath contribution + share-cap lift | 2032+ |
| GATED | Hemet replication | +1.5 | Executed facility agreement only | 2034+ |
| GATED | Chassis-replication fees | +2.5 | 2-3 partner sites × ~$1M | 2035+ |
| GATED | Hospital-at-home | +1.0 | Waiver-gated, mature book | 2033+ |
| **Full build** | | **+36.1** | **= ~+$20.1M — not underwritten** | **~2040** |

Ramp: 2026 -14.5 → 2027 -11.0 → 2028 -5.5 → 2029 -2.0 standalone → 2030 ~$0 standalone → 2031 consolidated break-even → 2035 +$6.1M.

## Capital

$69M committed; up to $94M with the accordion. Hospital bridge $39M against ~$34M cumulative losses: $12M MOB sale-leaseback, $18M receivables facility (upsizable $4M), philanthropy credited at 50% ($4M of an $8M campaign), and a $5M operator development-rights fee — headroom covers a one-year slip, the panel's exact failure case. NewCo: $30M operator capital with return-of-capital priority (80/20 waterfall to 1x, then 51/49), RCH 51% governance with reserved powers, partner operating control via MSO, and a binding FMV platform-fee schedule at 6.5% in the term sheet. The partner's yes is fee-plus-pipeline, not multiple-expansion — this pencils for a strategic operator building a national blueprint, and if none signs by mid-2027, the committee has still funded a break-even hospital.

## Moat

The turnaround is copyable; the option stack is not. One hospital to own in the corridor — internalized Part A at ~50 cents marginal cost, the single structural difference from Oak Street, Cano, CareMax, and agilon. Equity-locked independent panels that survive B&P 16600, raced against Optum and Astrana under SB 351's hospital exemption. A hospital-held institutional-risk position with an 18-24-month regulatory lead time. Kaiser can't serve non-Kaiser MA; LLU at 109% occupancy can't cannibalize its tertiary engine; Optum can't buy the hospital.

## Risks

The full register accompanies this chapter; the committee-grade five: deep-turnaround execution (a 25% miss delays break-even one year and triggers named deeper exits); the 340B/DSH interaction (modeled before the OB decision — adverse means OB stays); attribution shortfall or losing RYMG (a launch pre-condition with a defined walk-away; at 3,000 lives Block B falls to ~+$3.5M and Block A still carries break-even); no partner at honest economics (Block B dies; the funded outcome remains a break-even hospital); and a pre-agreed 2029 trigger — if standalone OI is worse than -$4M or quality gates miss, a banker-run affiliation process launches automatically.

## National vision

Roughly 700 fragile independent hospitals hold the asset every failed senior-risk disruptor lacked: the beds. The blueprint is sequence, not heroics — restructure to break-even first, then attach right-sized, attribution-verified senior risk with Part A internalized at marginal cost. Prove 4.7% of premium at Redlands, and the operator replicates it hospital by hospital: local hospitals solvent, seniors' physicians independent, and the Medicare dollar spent once, in a bed the community already owns.

---

*Strategy 5 of 5 — inserted as submitted; panel verdicts in Appendix A.*

# Mothership & Fleet 3.0 — Turnaround First, Buy Don't Build

## What changed after review

The panel failed version 2.0 on the clock (break-even Year 5), the branch (a greenfield flagship when Arrowhead's surgeons already own Advanced Ambulatory Surgery Center blocks from campus), and the plumbing (an ABL that likely violates a master-trust-indenture receivables pledge, a half-priced sale-leaseback, missing lease interest, an unpriced Title 22 OB floor, $6-10M of absent one-time restructuring costs, and a Tranche 1 too small for its own math). Version 3.0 changes structure, not adjectives:

1. **The plan is inverted.** The turnaround — restructuring, RCM, retention, midpoint recapture — is the committed base case: break-even Year 3 standalone, Year 4 combined. All JV income is gated until definitive documents sign.
2. **The flagship is re-branched to Track-B as base.** RCH buys ~40% of the surgeons' existing center (or a merged NewCo) at ~7x — cash liquidity to physicians who keep 60%, minority economics to RCH (+$2.2M, not +$4.5M). This converts an adverse negotiation ("hand us 51% of volume you keep 100% of") into a winnable one, and kills the construction clock: an operating center pays from close, not Month 33. Greenfield is a labeled upside branch, not underwriting.
3. **Every flagged line is re-costed.** OB right-size $2.3M to $1.5M (Title 22 L&D floors); MOB rent at full market (~$1.0M/yr); imaging finance-lease interest priced (line falls to +$0.2M); $8M one-time restructuring costs added to program capital; cannibalization re-derived at -$3.5M for a no-greenfield scope (-$5.5M stress retained).
4. **The liquidity keystone is replaced.** No ABL. The bond-document review (gross-revenue pledge, negative-pledge covenants against ~$170.5M of liabilities) is a Tranche-0 gate with ranked compliant alternatives — permitted-liens basket, FHA 242/241, bondholder consent, CA Distressed Hospital Loan Program if a window reopens — and a pre-agreed fallback (30% flagship stake) that delays income one year and breaks nothing.
5. **Seismic goes first.** AB 869 filing status confirmed within 30 days; the minimum-compliant-footprint engineering estimate becomes a senior capital line before Tranche 1. Unfunded need above ~$25M freezes Tranche 2 and opens a mothership capital-partner track.
6. **Year 1 is truly capped at four workstreams**; the MOB sale-leaseback (with its AG 5914-5925 process) and employer contracting move to Year 2. Anti-steerage payer contracts, the DMHC letter, and a coordinated OHCA pre-filing narrative become Tranche-0 conditions precedent. One CMIR now sits in the base case, not the stress case.
7. **The counterfactual is on the table.** Tranche 1 alone out-earns the combined plan through roughly Year 8. The board buys Tranche 2 explicitly as a defensive and strategic option — not an earnings strategy.

## Situation

RCH's data has voted: outpatient surgeries (3,871) exceed inpatient (2,854), outpatient is 58% of net revenue, discharges are down 31% since 2018, and site-neutral policy will strip the HOPD premium regardless. The correction the panel forced is that the other side of that migration already exists and is already owned — by the surgeons themselves (AASC), by SCA/Optum (Inland Surgery Center, 20-year incumbent), and by LLU (Barton Road surgical hospital). RCH's choice is not build-versus-lose; it is buy-in-versus-be-surrounded.

## The model: two engines, one gate structure

**Engine A — the committed turnaround.** A re-costed 3.0% restructuring (+$11.7M), RCM yield at 0.85% of net revenue (+$3.5M, below the 1-3% distressed-engagement band), midpoint surgical recapture (+$2.0M), medical-admission retention (+$1.5M), netted CMI lift (+$1.0M), and Year-2 employer contracts (+$0.8M). Engine A needs no Arrowhead signature, no new financing structure, and no regulatory luck. Standalone, it breaks even in Year 3.

**Engine B — the platform option, at Track-B economics.** Three recapitalizations of existing centers (flagship ~40%, GI ~40% behind a live LOI, multi-spec 51%), one gated Pass-corridor site, one wholly-owned imaging suite. At RCH-share equity-method income after JV D&A and debt service, the fleet earns +$5.0M against -$3.5M cannibalization and -$2.0M overhead: roughly P&L-neutral in the bankable window. We say that plainly. The board buys it for three reasons: the migration erodes the core in every scenario (~-$2.5M by Year 8 with no platform, growing), so capturing 40-51% of the other side is defense, not growth; whoever recapitalizes AASC and the GI center owns the county's elective future — if that is SCA or LLU, Engine A's base erodes faster; and Phase III (+$9-16M conditional) exists only if Phase I does.

## The bridge (run-rate, from -$16M)

| Lever | $M/yr | Basis (est) | Timing |
|---|---|---|---|
| Cost restructuring 3.0%, re-costed | +11.7 | 8 waves incl. OB at Title 22 floors ($1.5M); $8M one-times to capital | Yr 1-3 |
| Revenue-cycle yield | +3.5 | 0.85% of $407M net revenue | Yr 1-3 |
| Surgical recapture (midpoint) | +2.0 | ~310 discharges x $6.5k contribution | Yr 2-5 |
| Medical-admission retention | +1.5 | ~230 retained admissions x $6.5k | Yr 2-4 |
| CMI/periop lift (netted) | +1.0 | +0.02-0.03 CMI, recapture volumes excluded | Yr 3-6 |
| Occ-health/employer bundles | +0.8 | 12 self-funded employers; DMHC-lettered | Yr 2-5 |
| Flagship Track-B recap (40%) | +2.2 | 5,500 cases bottom-up from Medicare floor; 28% EBITDA; NI x 40% | Close Yr 2 |
| GI recap (40%, live-LOI gate) | +1.0 | $3.3M EBITDA at 6.5-7x; NI x 40% | Yr 1-2 |
| Multi-spec recap (51%) | +1.0 | $2.8M EBITDA; NI x 51% | Yr 2-3 |
| Pass-corridor ASC (gated) | +0.6 | Recycled distributions fund | Yr 5-7 |
| Imaging suite (re-costed) | +0.2 | EBITDA less D&A less lease interest | Yr 3-5 |
| HOPD cannibalization | -3.5 | ~1,100 steered cases x $3,200; stress -5.5 | Yr 2-6 |
| Platform overhead (slimmed) | -2.0 | No de novo development program | Yr 1+ |
| Financing/occupancy (full cost) | -2.4 | Market MOB rent $1.0M; interest $1.2M | Yr 2+ |
| **Committed subtotal** | **+17.6** | **= +$1.6M operating income Year 7** | |
| Phase III-A (5 sites, conditional) | +7.7 | Gated on TAM study + Phase I proof | Yr 8-11 |
| Phase III-B (6 sites, ceiling) | +9.2 | Not bankable today | Yr 11-15 |
| Partner buyout + platform effects | +4.0 | Pre-priced 5.5-6.5x; employer scale | Yr 7-14 |
| Phase III overhead | -2.5 | Regional layer | Yr 8-15 |
| **Conditional total** | **+36.0** | **= +$20.0M, Year 13-15 scenario only** | |

Sequence: Year 1 ≈ -$10.8M, Year 2 ≈ -$7.5M, Year 3 ≈ -$1.8M, Year 4 ≈ $0, Year 7 ≈ +$1.6M. Stress (cannibalization -$5.5M, second CMIR, low recapture): break-even Year 5 with the wave-4 trigger engaged.

## Capital

$55-60M total program; RCH cash $24-27M phased. Tranche 0 (~$1M): bond documents read, seismic status and engineering estimate, GI LOI, AASC ownership/valuation diligence, anti-steerage contracts signed, DMHC letter, OHCA pre-filing, 13-week cash forecast. Tranche 1 ($15-16M, NPV-positive standalone): restructuring one-times + GI equity + leadership. Tranche 2 ($9-12M): flagship and multi-spec, released only if the stress case still clears Year-5 break-even and liquidity is confirmed. Sources: MOB sale-leaseback $12-14M (Year 2, post-AG, full rent priced), philanthropy $5M, recycled distributions $3-4M, non-recourse JV debt ~$20M, and a $4-6M bridge only if the indenture permits — otherwise the 30%-stake fallback executes.

## Moat, honestly

No statute protects this. The moat is built deal by deal: a liquidity offer surgeons can take without surrendering control (against SCA's Optum strings and LLU's absorption model), a rate delta quantified in the term sheet and stressed to zero so the deal must stand on enterprise value, and — after signing — buy-sell economics and distributions that foreclose surgeon supply where B&P 16600 bars non-competes. Before signing, the moat is a 90-day diligence window and a walk-away price.

## Risks

Anchor negotiation with LLU counter-bidding; the indenture; seismic as a senior claim; GI lost to a roll-up (line deletes); rate-delta erosion; cannibalization overshoot; Optum's two-front response; CMIR bundling; qui tam exposure outside the ASC safe harbor; board bandwidth. Each carries a named gate, fallback, or deletion path — and the turnaround survives every one of them.

## National vision

This is the portfolio's Toyota, not its Tesla: fix the core with levers every community hospital owns, then join the ambulatory migration as the surgeons' minority partner instead of fighting it. Replicated across the ~600 independent hospitals in RCH's position, it keeps community care local, solvent, and independent of national consolidators — the unglamorous mechanism by which a top-tier nation actually improves outcomes per dollar.

---

# Portfolio & Sequencing

## The central finding

The five strategies are not five choices — they are one turnaround counted five times, one Arrowhead deal structured three ways, one senior-risk option designed twice, and one externalization idea in two vehicles, all bidding for the same three capital sources and the same four-workstream management ceiling. The portfolio job is deduplication, not selection.

## What combines (count once, build once)

1. **One ops engine.** Every strategy carries the same restructuring content — bed consolidation, ALOS 4.5→~4.0, CDI/CMI, denials, supply chain, premium-labor elimination — at overlapping dollar values ($10-19M gross each). Fund it once at the deepest specification: RedlandsOS's instrumented, benefit-realization-audited version (~$15-17M net run-rate swing), absorbing Strategy 2's command center as the operating hub and Strategies 3/4/5's "shared" lines. One transformation office, CFO sign-off on every claimed dollar, one bed-count target (~165-175 staffed, reconciled to the seismic minimum-compliant footprint — the current 160/170-180/175 spread across strategies must be resolved by census math once).
2. **One ambulatory engine.** Arrowhead Orthopaedics appears in Strategies 3, 4, and 5 with three different deal structures (51% new JV / 40% converted-wing / 40% Track-B recap of their existing AASC). The panel-verified market fact — the surgeons already own AASC — makes Strategy 5's Track-B recapitalization the only winnable structure (cash liquidity at a full multiple for a minority stake vs. asking surgeons to hand over volume they keep 100% of today). Execute it once, wrapped in Strategy 3's CIN so the ambulatory platform and the physician alliance are one negotiation, not two. GI recap gated on a live LOI; multi-spec in Year 2-3.
3. **One physician chassis.** Friendly-PC + MSO + CIN, built once, serving Strategy 3's MSO fees and recapture, Strategy 2's RPM/CCM, and (later) Strategy 4's SB 351 non-delegable risk-governance functions. One relationship owner for PHN, which appears in Strategies 2, 3, and 4.
4. **One senior-risk option.** Strategy 3's PHN MA-risk lever and Strategy 4's Block B are the same option. Take Strategy 3's counterparty and gates (FY2030 decision, attribution audit, stop-loss, RCH exposure capped $3-4M) with Strategy 4's underwriting discipline (realized-V28 $1,700/patient center contribution, hospital-side shift netted against baseline, DMHC 1300.49 exemption filed concurrently with a Restricted Knox-Keene application). Carried at corrected economics: +$8-12M at maturity, not +$9.7M to RCH alone.
5. **One externalization option, decided Year 3+.** RedlandsOS NewCo licensing and the member-owned co-op are two vehicles for the same idea (sell the audited playbook to 400+ struggling independents). Both require 2+ years of audited internal results first; pick one then; carry both at zero now.

## What conflicts (and how resolved)

- **Capital:** the MOB sale-leaseback ($12-14M) is claimed by Strategies 3, 4, and 5 — it spends once, in Year 2, after appraisal and AG 5914/5920 pre-clearance, rent booked at full market. The receivables facility (claimed at $15M and $18M by different strategies) is conditioned on the master-trust-indenture read — Strategy 5's panel is right that a gross-revenues pledge likely bars it; the read is Gate Zero for the whole portfolio, with FHA 242/241 or a permitted-liens basket as fallbacks. Philanthropy is one donor base: one unified campaign, realistically $6-8M, not the $24-29M the five strategies collectively assume. SilverPass's $39M bridge + $30M NewCo cannot coexist with any of this and is not funded.
- **Management bandwidth:** every panel independently converged on a 4-workstream Year-1 cap for a -$16M hospital with a January-2026 CEO. The portfolio honors it: (1) turnaround wave 1 under the TMO, (2) AASC diligence/term sheet (the 90-day window), (3) GI LOI-to-close, (4) CIN/friendly-PC/MSO formation. Everything else — MOB monetization, employer pilots, multi-spec recap, MA-risk gate work, Pass corridor, externalization — waits for Year 2+ by board covenant.
- **OB:** one Phase-0 340B/DSH model, one decision; default is Strategy 5's right-size-at-$1.5M (Title 22 floors priced), not Strategy 4's closure, because OB-closure headline risk poisons the one philanthropy campaign three strategies depend on.

## Recommended sequence

- **Gate Zero (90 days, before capital moves):** indenture read; AB 869/seismic filing status + minimum-footprint engineering estimate; unrestricted-cash verification; Phase-0 340B/DSH model; AASC diligence window opens; TMO + benefit-realization office stood up.
- **Year 1 (FY2027):** the four workstreams above; stroke-mortality remediation starts inside the quality budget (it is the diligence centerpiece for every partner conversation). Target -$16M → ~-$10M.
- **Year 2 (FY2028):** MOB sale-leaseback closes; AASC recap closes (one CMIR priced in base); 2-3 employer pilots signed; multi-spec term sheet. ~-$4M.
- **Year 3 (FY2029):** portfolio breakeven (P50 FY2030). MA-risk gate work: attribution audit, PHN term sheet, DMHC filing.
- **Years 4-8:** gated engines fire or don't. MA risk (decision FY2030) ramps to +$8-12M by FY2033-34 if it passes; ASC Phase III-A adds up to +$11M by Year 11-12 if Tranche gates pass; externalization decided on audited results.

## Portfolio arc, stated honestly

Breakeven FY2029 (P50 FY2030); +$8-12M by FY2031-33 (2-3% margin — top-quartile territory for a community hospital); +$15-20M in FY2034-36 only if two of the three gated engines pay — roughly 35-50% probability. Nothing faster survived three rounds of adversarial review, and the board should treat any plan that claims faster as unreviewed.

---

# The Tesla Answer

No single strategy is the Tesla, and the review process proved it the hard way: every pretender to the pull-away claim (Glass Hospital three times, the original Terracina, the original SilverPass) died in panel, and all five survivors now explicitly disclaim the label — Strategy 3 calls its own moat "Southwest's, not Tesla's." The honest answer is that the Tesla move is a **stack**, not a strategy:

**RedlandsOS** (the audited AI-native cost structure) × **the Independent Alliance** (an SB 351-protected coalition of the 188-group independent bench, PHN's ~54k lives, and Arrowhead's surgical franchise around the only independent full-stack hospital in the corridor) × **the internalized-Part-A senior-risk chassis** (SilverPass's one true insight: RCH owns at ~50 cents marginal cost the hospital days that Oak Street, Cano, CareMax, and agilon all died paying retail for).

Each layer alone is copyable operational excellence. Stacked, they create a position none of the four named predators can occupy: Optum cannot lead the coalition (it is the thing the independents are fleeing, and SB 351's hospital exclusion lets RCH offer alignment structures a payer/PE buyer legally cannot); Kaiser cannot join it (closed by design); LLU cannot price it (academic cost structure, 109% occupancy, tertiary FFS engine it will not cannibalize); a national DTC player has no beds, no ED, and no Part A. The moat is ownership identity + regulatory position + a three-year audited execution dataset — assets a copycat cannot buy in 36 months even with unlimited software budget.

The Tesla claim only matures at replication: if the stack works at RCH, the chassis — AI-native ops + alliance economics + hospital-anchored senior risk — franchises to the 400+ money-losing independent hospitals nationally (RedlandsOS licensing or the co-op, plus Strategy 4's G6 chassis-replication). That is genuinely a structural repositioning others cannot quickly copy. But it is carried at zero in the plan of record, exactly where Tesla's software-margin claims belonged in 2012. Tell the client plainly: we are funding Southwest, with a priced, gated, real option on Tesla — and the option only exists if the boring layers are audited first.

---

# The National Vision

America has roughly 400 independent community hospitals losing money the way Redlands does — not because their communities stopped needing care, but because a 2005 operating model meets 2026 costs, payers own the physicians, and the only exits on offer are absorption by a system, sale to private equity, or closure. Every one of those exits removes a community's negotiating power and, usually, its services. The Redlands portfolio is a test of a fourth exit.

The blueprint has three layers, and each answers a national failure. First, the AI-native operating core answers the productivity failure: if a 211-bed independent can audit its way from bottom-decile to median-plus margin without cutting bedside care — with a third-party-verified scorecard rather than vendor press releases — then the operating playbook itself becomes transferable infrastructure, licensable or shared at cost through a cooperative, the way rural electric co-ops once transferred a different kind of grid.

Second, the Independent Alliance answers the consolidation failure. The counterintuitive fact from the Inland Empire census is that independence is not dying — 188 independent groups persist in Optum's strongest market, and the ones that left told us why. A hospital that offers physicians alignment without acquisition, protected by California's own SB 351 asymmetry, converts independence from a nostalgia into a product. Nationally, that is the antitrust remedy no regulator can write: a viable economic home for physicians who do not want to be owned.

Third, hospital-anchored senior risk answers the fatal flaw of the last decade of value-based care. Oak Street, Cano, CareMax, and agilon all failed the same way — they managed seniors brilliantly in clinics and then paid retail for the hospital days, enriching the very facilities whose costs they were supposed to bend. A community hospital that holds the risk AND the beds internalizes Part A at marginal cost. If that chassis works in Redlands, it works in every one of the hundreds of markets where exactly one independent hospital sits amid an aging population — and Medicare's cost curve bends where it actually breaks: in the hospital, not around it.

A top-tier nation's health system is not defined by its academic medical centers, which are already world-class. It is defined by whether an ordinary community can keep a solvent, high-quality, locally governed hospital without selling it. If the Redlands stack — audited operations, alliance economics, owned risk — reaches top-quartile margin and replicates even a dozen times, the default fate of the American community hospital stops being absorption or closure and becomes something the country has not had in a generation: a franchise model for staying independent. That is the national blueprint hiding inside a $407M hospital's turnaround.

---

# Board Decision Memo

**TO:** Board of Directors, Redlands Community Hospital
**FROM:** Managing Partner, strategy engagement
**RE:** Portfolio decision — from -$16M to breakeven to the honest ceiling

## Decision requested

Approve one funded portfolio, not a choice among five strategies: (1) the RedlandsOS operational transformation as the mandatory base layer, absorbing the command-center concept and every overlapping restructuring line from the other four plans, counted once; (2) the Independent Alliance — CIN, friendly-PC/MSO, employer-direct — as the demand engine; (3) the ambulatory platform executed buy-don't-build (Arrowhead/AASC recapitalization at Track-B economics; GI recap gated on a live LOI); and (4) two gated options carried at ZERO in the plan of record — the PHN senior global-risk book (decision FY2030, underwritten at realized-V28 economics with internalized Part A) and externalization of the audited playbook (RedlandsOS NewCo or co-op, decision Year 3+). Redlands Unbound and SilverPass are not funded as standalone programs; their unique components are absorbed as specified in the portfolio plan.

## The honest numbers

Base case: breakeven FY2029, P50 FY2030. +$8-12M operating income by FY2031-33 — roughly 2-3% margin, top-quartile territory for a community hospital. +$20M is real but conditional: it requires two of three gated engines (MA risk, ASC Phase III-A replication, playbook externalization) to pay, landing FY2034-36 at roughly 35-50% probability. No plan that claims +$20M faster survived three rounds of adversarial review.

## Order of operations

Gate Zero, next 90 days, before any capital moves: read the master trust indenture (it conditions all receivables-based liquidity); confirm AB 869/seismic filing status and price the minimum-compliant footprint; verify unrestricted cash; run the Phase-0 340B/DSH model before any OB decision; open the Arrowhead/AASC diligence window; stand up one transformation office with a benefit-realization function holding CFO sign-off on every claimed dollar. Year 1 runs exactly four workstreams: turnaround wave 1, AASC term sheet, GI LOI-to-close, CIN/friendly-PC/MSO formation — with stroke-mortality remediation funded inside the quality budget from day one. MOB sale-leaseback, employer pilots, and the multi-spec recap move in Year 2. MA-risk gate decision FY2030.

## Capital

~$40-45M external over four years; the balance sheet funds nothing. Sources, each counted once: $12-15M receivables or alternative facility (post-indenture read; fallbacks are a permitted-liens basket or FHA 242/241); $12-14M MOB sale-leaseback in Year 2 after appraisal and AG pre-clearance, rent booked at full market; $6-8M from a single unified philanthropy campaign; $4-5M vendor at-risk contract value; ~$6.5-10M staged JV equity with ~$20M non-recourse debt at the center level. The five strategies collectively assumed $24-29M of philanthropy and spent the same MOB and receivables twice and three times; this plan does not. SilverPass's $30M operator check is excluded — if a fee-first operator signs at honest economics by 2027-28, it accelerates the risk option as upside, never underwriting.

## What we stop

Staffing 211 beds (consolidate to a census-derived ~165-175, reconciled to the seismic footprint); greenfield ASC construction; registry dependence as a permanent posture; generic brand advertising; marketing against the structurally locked 70% of leakage; executive health (conceded to LLU); the consumer longevity membership; all pre-contract capex; more than four concurrent major workstreams.

## Tripwires

If FY2029 standalone operating income is worse than -$4M, or the CMS 3-star and stroke gates miss, the pre-agreed banker-run affiliation process opens automatically. If the indenture bars new liens and consent fails, tranches shrink to the severable turnaround-only variant, which still reaches breakeven in Year 3-4. The board is buying a funded breakeven with two priced options on top-quartile performance — and it should reject any future version of this plan in which a gated option has quietly become load-bearing.

---

# Appendix A — Panel Verdicts

*Full outputs of the three-lens adversarial review, organized by strategy and lens. "Confidence" is the panel's self-reported 0-100 score. Fixes and notes are reproduced as issued by each panel.*

## A.1 Strategy 1 — RedlandsOS: The AI-Native Lean Hospital

### Financial realism

**Verdict: VIABLE — confidence 60/100.** Fatal flaws: none.

**Required fixes noted:**

- Add a quantified baseline-drift line to the bridge: the run rate deteriorated from -$8.6M audited (FY2024 990) to -$16M client-stated in ~18 months, and inpatient discharges are still decaying ~3%/yr (9,604 FY2024 vs 10,180 FY2022). The bridge freezes the baseline for 5 years; even $2M/yr of continued drift consumes the entire +$3.3M steady state. State the flat-volume dependency on a paired growth strategy IN the bridge, not just the risks section — standalone against continuing decay, this strategy never reaches breakeven.
- Correct the breakeven arithmetic: at the stated ~75% benefit capture, FY2029 computes to ~-$3.9M (0.75 x $28.6M gross - $9.3M run-rate costs = +$12.15M swing), not $0. Breakeven requires ~88% capture (~95% excluding the not-yet-real licensing line). Restate breakeven as FY2030 (program Year 4 — still inside the 3-4yr window) or defend the higher capture rate.
- Re-source the $8-12M sponsor-equity plank of the $28M capital stack: the strategy's own text says licensing requires 2+ years of audited results first, so no growth investor funds the NewCo at that size in Years 1-2 (Ensemble's $1.2B/51% deal followed years of operating proof) — and NewCo equity legally/practically cannot fund the hospital's internal transformation (related-party transfer investors would block). Fix: phase the $18M build, self-fund later phases from early denial/staffing capture, move the NewCo raise to FY2029 post-proof. Realistic Year 1-2 capital is ~$13-16M (vendor at-risk equivalent + philanthropy + IT financing) vs $18M build.
- Verify actual registry/traveler/OT/premium spend against the GL before banking the $5.9M staffing lever (the single largest bar): the $13M base is an estimate (5-6% of ~$225M labor); Kaufman Hall shows contract labor normalizing industry-wide from its ~11%-of-labor 2022 peak, so RCH's FY2027 base may be $8-10M — a $1.5-2.5M haircut on the biggest lever.
- De-duplicate overlapping levers: HIM labor appears in both the coding/rev-cycle lever (+$3.5M, "coding/billing/HIM") and the agentic back-office lever (+$3.2M, "prior auth, scheduling, HIM, finance, HR"); CDI-driven documentation improvement also reduces clinical-validation denials counted in the +$3.4M denials lever. Apply a ~$1.0-1.5M consolidation haircut across the three.
- Cut or source the $1.2M OR/ED throughput backfill inside the flow lever: at 56.6% occupancy, beds freed by ALOS reduction have no queued demand. Name the specific demand source (ED boarding-to-admission conversions, transfer-center acceptance) or remove it — and confirm at portfolio level that no growth strategy claims the same recaptured volume (cross-strategy double-count risk).
- Present steady state with AND without the +$2M RedlandsOS licensing line: "option not plan" cannot sit inside the base P&L bridge. Without it, steady state is ~+$1.3M (margin ~0.3%), which is the honest base case; licensing is upside.
- Scale-check the rev-cycle complex against audited comparables: Auburn's audited CAC financial impact was ~$1.03M at 99 beds; this bridge books ~$10.1M across CDI+denials+coding at 211 beds (~5x per bed). The CDI %-assumption (2.5% vs Auburn's 4.6% CMI) is conservative, but the denials lever (0.85 pts of NPR recovered, roughly halving final write-offs) and 40% coding-labor removal are at the aggressive edge — tie each to an at-risk vendor guarantee or haircut to ~70%.

**Panel notes:** CONDITIONAL PASS — viable in its self-described role (portfolio margin engine paired with a growth strategy), NOT viable as a true standalone. The bridge sums correctly (-16 + 28.6 - 9.3 = +3.3M), every cited benchmark checked out as real (Auburn +4.6% CMI per AHA; Jackson Health 0.42d/$6.7M per Qventus; Kaufman Hall median margin 1.3% CY2025), the ceiling is honestly stated below +$20M with a band that includes $0, steady-state margin (0.8%, band 0-1.5%) sits below the verified 1.3% industry median, and the vendor at-risk contracting is a real market structure. What keeps confidence at 60: (1) ops-only net capture of ~$17.3M = ~4.2% of the $415M expense base, at/above the top of the strategy's own cited 2-4% documented AI ceiling — expected case after haircuts is breakeven-to-+$2M in FY2030-31, the bottom of their band; (2) the FY2029 breakeven claim contradicts its own 75%-capture statement (computes to -$3.9M; needs ~88-95%); (3) the static -$16M baseline ignores the client's own -$7.4M run-rate deterioration over ~18 months — the flat-volume assumption only holds if a paired growth strategy delivers, which the strategy admits; (4) $8-12M of the $28M capital stack (pre-proof NewCo sponsor equity) is not credibly available for the internal build in Years 1-2 and must be replaced by phasing + self-funding from early capture. Against the lens test: breakeven by Year 4 (FY2030) is credible under the fixes; the honestly-stated ceiling (+$0-6M, base ~+$1.3-3.3M) is reachable by FY2031. IC recommendation: approve as the mandatory enabling layer for whichever growth strategy the board picks, with a benefit-realization office holding CFO sign-off, GL verification of the registry base as a stage-gate, and the corrected FY2030 breakeven in board materials. RedlandsOS licensing/equity is genuine option value (Ensemble precedent) but must be carried at zero in the plan of record. Sources: kaufmanhall.com National Hospital Flash Report Dec 2025; aha.org Auburn Community Hospital AI rev-cycle case; agshealth.com Auburn CAC $1.03M case study; qventus.com Jackson Health case study PDF; healthcaredive.com Kaufman Hall contract-labor series; baseline financials from rch_financials_utilization.csv (FY2024: $407.1M rev / $415.7M exp / 9,604 discharges / ALOS 4.5d).

### Market and competitive realism

**Verdict: NOT VIABLE as submitted — confidence 72/100.**

**Fatal flaws:**

- Frozen-baseline fallacy: the bridge nets +$19M against a static -$16M, but the client's own 990/HCAI data shows ~-$3.7M/yr deterioration (FY2023 +3.9% on $418.3M -> FY2024 -2.1% on $407.1M -> -$16M today), with nominal revenue now declining, discharges -31% since 2018, births -38%. At that decay rate the FY2029 baseline is -$24M to -$28M, and the program lands at -$5M to -$9M — the headline "breakeven by FY2029" is not credible standalone. The strategy admits it fixes margin, not demand ("MUST be paired with a growth strategy"), which is a self-disqualification from the mandate's standalone break-even test.
- Revenue-side levers shrink with the market they sit on: the CMI uplift (+$3.2M) is computed on ~$130M of DRG-paid inpatient revenue that is itself contracting ~6%/yr in volume; each additional decay year strips ~$200k+ off that lever and shrinks the denominator the denials lever works against. The bridge treats volume-linked gains as fixed annuities.
- No payer counter-response modeled: the denials lever (+$3.4M) assumes payers hold still, but UnitedHealth Group — whose Optum arm owns Beaver, the dominant local physician group and the strategy's named adversary — is the industry's most aggressive deployer of claims/denial AI, and industry initial-denial rates are RISING precisely because of payer-side automation. This is an arms race with capture decay, not a one-time fix; several points of the +$3.4M evaporate on contact.
- The $1.2M OR/ED throughput backfill is partially hoped, not sized: at 56.6% occupancy, freed bed-days are empty beds with no marginal demand behind them. ED throughput has a real demand basis (ED visits grew 38,904 -> 61,472 since 2018), but no constrained resource (boarding hours, LWBS, OR block utilization) is named or evidenced from the HCAI data, and OR backfill has no support — outpatient surgery is already growing without a capacity-constraint claim.
- The RedlandsOS "segment trust" seat is already occupied: Premier Inc. and Vizient are member-owned and literally exist to be the not-Optum trusted advisor to independents; Providence spun out Tegria and Intermountain spun out Castell (the exact health-system-services precedent); Ensemble, Huron, Chartis, and state hospital associations all sell into this segment. The buyers are money-losing hospitals with no discretionary budget and 12-18-month sales cycles, and a reference site showing ~1% operating margin is a modest calling card. Correctly modeled at only +$2M as an option — but the Ensemble $1.2B/51% equity comp (a ~$900M-revenue RCM company at scale) is a story that has no business appearing near this bridge.

**Required fixes noted:**

- Add an explicit baseline-decay line to the bridge (-$2.5M to -$4M/yr through FY2029, basis: the FY2023->current documented trajectory) and restate the break-even year against the moving baseline — or formally fuse this strategy with one named growth strategy and publish a single combined bridge with no double-counting. As written, the break-even date is an artifact of a frozen denominator.
- Re-base the throughput lever: keep the ~$1.8M non-labor variable savings (real), keep only the ED share of the $1.2M backfill tied to a named, measured constraint (ED boarding hours, left-without-being-seen rate — ED demand genuinely grew 58% since 2018), and strike OR backfill unless HCAI block-utilization evidence is produced.
- Model the denials lever with payer counter-response decay (e.g., 33-50% capture erosion over 3 years as UHG/Elevance/Blue Shield escalate their own AI) and structure vendor at-risk fees on net-of-payer-response verified recovery, not gross overturns.
- Reposition RedlandsOS comps from Ensemble to Tegria/Castell (health-system services spin-outs — the honest precedent, including their mixed results); require 5 signed LOIs from target independent hospitals before releasing any of the productization tranche; keep licensing at $0 in the plan-of-record bridge (the write-up already treats it as option — enforce that discipline in the capital plan too, since $8-12M of the $28M raise depends on the NewCo story).
- Pressure-test the $8-10M philanthropy ask against the RCH foundation's actual historical campaign capacity — "AI-native efficiency" is a harder donor story than a NICU or cancer center; reframe around 120-year institutional survival and named capital assets, and get a feasibility study before the number goes in the capital stack.

**Panel notes:** Verdict is NOT viable as a standalone answer to the mandate, but this is the highest-quality failure in the portfolio and the review should not be read as kill-it. Strengths on this lens are real and rare: (1) it is the single most competition-proof strategy available — no customer (employer, payer, senior, consumer) has to switch anything, and Optum/Kaiser/LLU literally cannot block RCH from cutting its own costs; running their own versions doesn't take a dollar from RCH's capture; (2) vendors have genuine incentive to co-fund (a verified independent-community reference site is worth more to Qventus/LeanTaaS-class vendors than the fee risk), so the at-risk contracting assumption is market-realistic; (3) the moat section and the sub-$20M ceiling admission are investment-grade honesty — the benchmarks (Auburn +4.6% CMI, Jackson -0.42d) are real and applied at ~half strength. The correct board framing: this is mandatory infrastructure that must run underneath whichever growth strategy wins, with its bridge restated against a decaying baseline and its break-even claim owned jointly with that growth strategy. Standalone, the market's own vote — -6%/yr discharges, declining nominal revenue, a payer adversary that owns the dominant local physician group — eats the swing before it lands.

### Regulatory and execution

**Verdict: VIABLE — confidence 60/100.** Fatal flaws: none.

**Required fixes noted:**

- RE-WAVE THE PROGRAM OR IT FAILS THE CONCURRENT-INITIATIVE CAP: as scheduled, FY2027 launches ~7 workstreams simultaneously (CDI, denials, autonomous coding, flow, staffing/float pool, agentic back office, ambient) PLUS transformation-office standup PLUS a 3-track capital raise — at a 1,847-employee hospital with a CEO in seat ~12 months, and the thesis says this runs CONCURRENT with a growth strategy. No 211-bed independent absorbs 10 concurrent efforts. Fix: hard cap of 3 active workstreams; Wave 1 (FY2027) = rev-cycle only (CDI+denials+autonomous coding, ~$10.1M of levers, CFO-owned, minimal clinician touch); Wave 2 (FY2028) = flow + staffing; Wave 3 (FY2029) = back office/supply chain/energy/ambient. Accept and state breakeven FY2030, not FY2029.
- FIX THE CAPITAL SEQUENCING HOLE: the $18M build is front-loaded FY2027-28, but realistically available cash in that window is ~$8-12M — vendor at-risk is fee relief not cash; an $8-10M philanthropy campaign pays out on 3-5-year pledge schedules (~$2-3M cash in year 1); and sponsor equity logically arrives only AFTER the 2+ years of audited results the strategy itself says licensing requires (Ensemble's $1.2B deal followed a decade of Bon Secours operating results — no growth investor writes $8-12M against a playbook that does not yet exist). Fix: size Wave 1 to committed cash (philanthropy first tranche + $4-6M IT financing), require signed at-risk vendor contracts with >=40% contingency before launch, and move sponsor equity to a FY2029 NewCo-only event that never funds hospital opex.
- NAME THE EHR — the plan's largest unpriced variable: an "AI-native rebuild" whose bridge never states what EHR/data platform RCH runs. Ambient, autonomous coding, CDI, and flow AI all ride on EHR integration; Qventus/CodaMetrix-class vendors deliver fastest on Epic/Oracle Health. If RCH's current platform cannot support the stack, a mid-program EHR migration adds $10-20M and ~18 months and invalidates the FY2029 breakeven. Board deck must include an EHR-dependency map and vendor-certified integration commitments before any contract is signed.
- PAPER THE AMBIENT-AI SUBSIDY UNDER STARK/AKS: ~150 recipients are mostly independent medical staff — i.e., referral sources — so hospital-funded ambient documentation is remuneration. Structure under the EHR items/services Stark exception (42 CFR 411.357(w)) and AKS safe harbor (42 CFR 1001.952(y)) with the required ~15% physician cost-share, or charge FMV. Currently unaddressed in the bridge; also note B&P 650 (California kickback) applies. Not fatal, but an OIG-obvious exposure if launched unpapered.
- DO NOT ASSUME THE NEWCO IS BELOW OHCA THRESHOLDS: AB 1415 (effective 1/1/2026) explicitly extends OHCA material-change notice to MSOs and NEWLY CREATED ENTITIES — a services NewCo with PE/growth sponsor equity is the exact fact pattern the statute targets. Budget the 90-day notice (and possible CMIR delay) into the FY2029 licensing timeline rather than asserting "below thresholds, counsel to confirm." Also required: independent FMV valuation of the contributed IP + Corp. Code 5233 self-dealing process (nonprofit contributing assets for founder equity alongside for-profit investors), and a taxable-subsidiary structure so managed-services income is not UBTI at the 501(c)(3).
- DE-RATE THE FLOW LEVER FOR POST-ACUTE REALITY: RCH's ALOS went 3.5 to 4.5 days while payer mix skewed Medi-Cal-heavy — excess days at IE community hospitals are disproportionately SNF-placement/conservatorship/unfunded-discharge days that AI can surface but cannot discharge to. Jackson Health's -0.42d rode a large system's post-acute network RCH lacks. Either pair the flow tool with contracted SNF/recuperative-care capacity or cut the lever from $3.0M to ~$1.5-2M and rebuild the bridge.
- COMPLIANCE PUNCH LIST BEFORE GO-LIVE (all manageable, none optional): AB 3030 disclaimers on any generative-AI patient-facing communications from the agentic back office; Title 22 CCR 70217 nurse-ratio floors hard-coded into the staffing engine (the $5.9M lever must come only from above-ratio registry/premium spend — it currently does, keep it that way); HIPAA BAAs + CMIA + model-training/data-use clauses in every vendor contract; CCPA/ADMT risk assessment for predictive scheduling of employees (California employee data is covered); NLRA effects-bargaining plan if any bargaining units exist; Cal-WARN (Labor Code 1400 et seq.) contingency if attrition mismatch ever forces 50+ position actions in 30 days — a broken no-layoff covenant is both a legal notice problem and the death of the CIN recruiting pitch.
- TALENT AS A GATING CONDITION, NOT A LINE ITEM: recruiting a credible CAIO to a bottom-decile-margin 211-bed independent is a 6-9-month search and the single earliest slip driver; the benefit-realization office (CFO sign-off, positions-off-budget audits) is the difference between this bridge and fiction — RCH has run negative margins in 7 of the last 11 years with no sustained improvement program on record. Sign the CAIO and benefit-realization lead BEFORE board approval, and tie every vendor at-risk payment to audited, position-eliminated dollars.

**Panel notes:** Why viable on this lens despite the default-skeptical posture: this is the regulatory-cleanest strategy in the option set — no physician employment (CPOM untouched; no 1206(l) or friendly-PC needed), no risk-bearing (no Knox-Keene rung), no change of control (Corp. Code 5914 AG review not triggered), no new facility licensure. The only real regulatory work is papering (Stark/AKS on ambient, AB 1415 notice on the NewCo, AB 3030/CCPA-ADMT/Title 22 compliance hygiene) — all standard, none structural. And the strategy is unusually honest: it states a ceiling (~+$3.3M, band $0-6M) below +$20M, treats licensing as an option not a plan, and pre-names its own failure mode (unaudited benefits). That honesty passes the committee test the other strategies must be measured against. Execution is the binding constraint: as written, FY2027 concurrency and the capital-timing hole would sink it; with the re-waving and phased build above, realistic slip is 12-18 months — breakeven FY2030 (year 4, inside the ~3-4-year window at its edge) and the stated ceiling by FY2031-32 (well inside 7-8 years). Two lens-specific cautions for the committee: (1) baseline decay is the clock — discharges are falling ~6%/yr and this strategy fixes margin, not demand, so it only "reaches" breakeven if a growth strategy holds revenue roughly flat; the board should treat the two as one funded program with one transformation office, not parallel initiatives. (2) The moat claim is correctly modest — grade this as the margin engine and option, and reject any future version of the plan where RedlandsOS licensing revenue becomes load-bearing for breakeven. Confidence 60 rather than higher because two facts are unverifiable from the file set: the EHR platform (largest unpriced execution variable) and union status (effects-bargaining exposure).

## A.2 Strategy 2 — Redlands Unbound 2.0: Fix the Core, Share the Center

### Financial realism

**Verdict: VIABLE — confidence 55/100.** Fatal flaws: none.

**Required fixes noted:**

- Re-time break-even to a P50 case: Year-4 core breakeven requires all nine hospital-side levers (gross $19.75M) at 100% run-rate against $3.75M hospital-side overhead — an exact zero-slack offset of the -$16M baseline. With the plan's own acknowledged 6-12 month CNA/SEIU delay on the $5.25M labor levers (bed consolidation + tele-sitting) and the CMS 3-star gate on the $2M recapture lever, realistic core breakeven is Year 5. Present P50/P90 attainment cases; the current Year-4 claim is a P90 scenario labeled as base.
- Add a baseline-erosion line: discharges fell 13,946 (2018) -> 10,180 (2022) -> 9,604 (2024) per the HCAI file, yet the bridge holds the -$16M baseline flat. Even 1.5-2%/yr continued decline is a $1-2M/yr contribution headwind by Year 4-5 that no lever currently carries — this alone can consume the entire +$1-2M planning-case ceiling.
- Land an anchor commitment before Tranche A: $14M of the $22M (philanthropy $6M + PRIs $8M) is uncommitted, and $8M of health-foundation PRIs for a hospital operational turnaround is out of market — typical health PRIs run $1-3M per funder and flow to FQHCs/housing/community clinics, not acute-care command centers, and "repaid from documented savings" is a weak credit. Either secure a lead PRI/philanthropy commitment or substitute HCAI Cal-Mortgage-insured debt for part of the PRI tranche. The plan's own start condition (Tranche A fully committed or no start) makes this the gating fix.
- Rebase the CMI-capture math to DRG-paid discharges only: 0.02 CMI x all 9,604 discharges x $7,000 assumes every discharge is DRG-sensitive; Medi-Cal per-diem/capitated and delegated MA volume does not respond to CDI. At a realistic 55-70% DRG-sensitive share the line is ~$0.8-1.0M, not $1.35M (denial-prevention conservatism partially offsets, but show it).
- Add an explicit interaction adjustment between the ALOS lever (4,800 days x $450/day cash variable) and the 30-bed unit closure (32 FTE x $105k): if the $450/day variable includes flexed nursing labor on the closing unit, $0.5-1M is double-counted between the two levers.
- Bottom-up the command-center overhead: -$1.75 to -$2.0M for a 24/7 center running tele-sitting, flow, transfer, documentation support, and home-care logistics for RCH AND servicing 12-15 external members on a $7.5M book is thin — a 24/7 roster of 4-6 concurrent seats is ~20-25 FTE = $2.5-3.5M plus platform. Reconcile which staffing sits inside lever haircuts versus this line; likely $1M understated.
- Publish the co-op price sensitivity: blended ~$500k/member is 3-6x Avel's realized blended ~$77-153k/site ($92M FY24 across 600-1,200+ sites, verified). The comprehensive-bundle-only mix argument (credit-qualified small hospitals buying $300-800k bundles, no schools/LTC dragging the average) is defensible but unproven; show the consolidated P&L at blended $250-350k — at that level co-op contribution net of the $1M growth org is ~$0-0.3M and the planning case falls from +$1-2M to ~breakeven. Keep the 3+ signed-LOI-at-modeled-pricing precondition hard.
- De-risk the home-based-care ramp: 700 SNF-at-home/ED-to-home episodes at $2,100 contribution by Yr2-4 requires MA/commercial episode contracts that do not yet exist in an Optum/IEHP-dominated payer market; state which payers, the contracted-lives coverage needed, and whether field staffing (community paramedics/RNs) sits inside the $2,100 contribution or in the overhead line.

**Panel notes:** MARGINAL PASS — this strategy earns viability through honesty and bounded downside, not upside. The bridge arithmetic closes exactly: +$21.75M gross - $4.5M new overhead = +$17.25M net vs -$16M baseline = +$1.25M, matching the stated +$1-2M Year-6 planning case; conditionals (+$3.75M) reconcile to the ~+$5M Yr7-8 ceiling. Volume denominators match the HCAI source file (9,604 discharges, 43,416 patient days, ALOS 4.5 vs 3.5 in 2018, 211 licensed beds, 56.6% occupancy). No material double-counting found in the demand levers: transfer keepage + quality-gated recapture = 780 discharges = 28% of the re-underwritten 2,500-3,100 winnable pool, and their combined $3.5M sits inside the engagement's own $2-5.5M recapture band. Rule 4 is satisfied plainly: +$20M is declared unreachable; steady-state margins are at or below ceilings (0.3% consolidated vs 1-3% community-hospital typical; co-op 13-15% net vs Avel's verified mid-teens EBITDA). External benchmarks verified by search: Avel eCare $45M FY21 -> $92M FY24, EBITDA negative -> mid-teens (avelecare.com/driving-profitability-and-growth; comvest.com), supporting both the pricing comp and the realized ~$77-153k/site blended figure; AHCAH extension through 9/30/2030 confirmed (PL 119-75 Sec. 6210, CAA 2026; ama-assn.org, qualitynet.cms.gov) — correctly booked at $0 in the planning case. J-curve treatment is honest: Tranche C gated on 3+ LOIs + 3-star CMS + 12-18 months internal proof; conditionals excluded; severable $14M hospital-only variant plateaus near $0. The two near-fatal contingencies keeping confidence at 55: (1) break-even timing has zero slack — Year-4 core breakeven needs 100% lever attainment (levers 1-9 = $19.75M gross vs $3.75M hospital overhead = exact $16.0M offset), so P50 is Year 5, at the edge of but arguably within the ~3-4yr bar given the plan's staged, non-dilutive capital means a slip costs time, not solvency; (2) $14M of $22M capital (philanthropy + PRI) is uncommitted with the PRI tranche sized 3-5x the market norm for this use case — but the plan self-imposes a hard no-start gate, so the downside is non-launch, not capital destruction. Net expected value honestly re-underwritten here: consolidated ~$0 to +$1M by Yr6 (vs claimed +$1-2M) after baseline erosion and co-op price sensitivity — still break-even-class, which is exactly the foundation-layer role the thesis claims. Sources: https://www.avelecare.com/driving-profitability-and-growth/ ; https://comvest.com/comvest-credit-partners-announces-investment-in-avel-ecare/ ; https://www.ama-assn.org/public-health/population-health/lawmakers-extend-cms-hospital-home-waiver-five-years ; https://qualitynet.cms.gov/acute-hospital-care-at-home

### Market and competitive realism

**Verdict: NOT VIABLE as submitted — confidence 68/100.**

**Fatal flaws:**

- The co-op planning book is mispriced against its own comp, and the only positive consolidated income disappears when demand-weighted. Avel eCare's verified economics are $92M FY24 revenue across 1,200+ sites — roughly $77k realized per site average — yet the planning case needs 12-15 members at blended ~$500k/yr. The buyers who need comprehensive bundles most are the ones who cannot pay: San Gorgonio Memorial (the strategy's archetypal CA district prospect) runs 2,101 discharges at 27.5% occupancy on a parcel-tax lifeline — a $75-150k modular buyer at best. Credit-qualified stable systems have the money but less burning need and will comparison-shop Avel/Access TeleCare modular pricing. A demand-weighted blended of $150-250k/member yields ~$2-3.5M services revenue and ~$0.5-0.9M contribution against the -$1M growth org — the co-op layer nets roughly zero-to-negative, so the strategy misses even its honestly-stated +$1-2M Year 6 ceiling; the most probable market outcome is the ~$0 hospital-only plateau the strategy itself describes as the severable fallback.
- The ownership-economics moat — the strategy's one surviving structural claim — is already being organized by an established competitor in exactly the out-of-state Wave 1 lane. Cibolo Health's member-owned high-value networks (Rough Rider: 23 ND hospitals/41 clinics; Headwaters: 19 MN hospitals; Ohio HVN: 26 hospitals) sell precisely the "farmers co-op" governance pitch including shared virtual specialist access. A CAH that joins one buys virtual services through its own network, not from a 2-star California hospital's brand-new co-op 1,500 miles away, and RCH's other claimed moat (IE paramedic last mile) does not ship out of state. Wave 1 therefore competes against both scaled for-profit incumbents (Avel, Access TeleCare, Equum, Hicuity) on price AND a scaled co-op organizer on governance — with neither advantage.
- Consolidated break-even already sits at Year 5 (outside the ~3-4 year bar) and requires ~95% of the $21.75M gross bridge to land; the ~$7M market-facing slice faces costless competitor counters. Optum can tighten steerage of Beaver's ~1,000-clinician panels against the 780-discharge recapture/keepage assumption (28% of the re-underwritten 2,500-3,100 winnable pool) at zero cost to itself, and CMS overall star ratings run on a 2-3 year data lag — improvements begun Year 1 plausibly do not surface in the public rating until Year 4, making the "CMS 3+ by Year 3" gate that unlocks both the +$2M recapture lever and Tranche C roughly a year optimistic. Realistic consolidated break-even slips to Year 6.

**Required fixes noted:**

- Reprice the planning-case co-op book to demand-weighted evidence: blended $150-250k/member (modular-majority mix per the Avel realized comp), then either expand target membership to 20-30 or book the co-op layer at ~$0 net through Year 6 and move the +$2M contribution to the conditional column alongside CA HaH. Keep the 3-LOI-at-modeled-pricing gate — it is the right mechanism; the modeled pricing behind it is what must change.
- Repoint Wave 1 sales: stop competing with Cibolo-style networks for individual out-of-state CAHs and instead sell the command center as white-label infrastructure TO high-value networks (one contract covering 19-26 sites, e.g., a Headwaters- or Ohio-HVN-type buyer that has governance but no 24/7 clinical operations utility) and to California districts where no such network yet exists — the defensible position is "the only hospital-operated, cost-plus command-center utility in California," not "another vendor in the Dakotas."
- Underwrite the +$3.5M recapture/transfer-keepage slice against the Optum steerage counter explicitly: dated CIN signings of the named independents (CAMG, RYMG, Arrowhead Orthopaedics, PHN IPA) as attribution and referral defense, plus a formal LLUMC decompression/repatriation agreement — LLUMC runs at 109% occupancy and needs a community-acuity release valve, which converts the transfer lever from contested to partner-endorsed.
- Re-time the quality gate to CMS data-lag reality: commit to measure-level milestones (stroke 30-day mortality remediation, ED throughput, sepsis) in Years 1-2, expect the public 3-star rating in Year 4, and substitute Leapfrog participation plus payer-facing measure-level evidence for co-op sales credibility so neither recapture nor Tranche C waits on the star-rating publication cycle.
- Publish a 60%-lever-capture sensitivity: show what consolidated Year 6 looks like if Optum steerage and star-lag cut the market-facing $7-9M in half, and demonstrate the ~$4M contingency plus philanthropy/PRI structure survives a Year 6 break-even without triggering the growth-equity option prematurely.

**Panel notes:** This is the most honestly-architected strategy in the set, and the verdict is close. What survives attack: the $12.75M demand-independent internal turnaround (ALOS, CDI, supply chain, census-founded bed consolidation) is sized from RCH's own HCAI data and is market-proof; the AHCAH facts check out (extended to 9/30/2030 by P.L. 119-75, Feb 2026 — the strategy's sunset date is accurate and booking $0 for CA HaH is correct conservatism); the LOI/stars/tranche gating means failure degrades to a break-even core rather than a crater; and member-owned co-ops are a real, validated model — Cibolo's growth proves the niche exists. The failure is narrower but decisive on this lens: the single layer that produces positive consolidated income is priced 3-6x above the realized comp the strategy itself cites, and the governance niche it targets is being enrolled right now by an incumbent organizer. Verdict would flip to viable-as-foundation-layer (ceiling ~$0 to +$1M, break-even Year 5-6) with fixes 1-3 applied — but then it must be presented in the portfolio as the de-risking base other strategies stack on, never as a standalone path. Sources: Avel eCare growth/revenue disclosures (https://www.avelecare.com/driving-profitability-and-growth/, https://comvest.com/comvest-credit-partners-announces-investment-in-avel-ecare/); AHCAH extension (https://www.ama-assn.org/public-health/population-health/lawmakers-extend-cms-hospital-home-waiver-five-years, https://qualitynet.cms.gov/acute-hospital-care-at-home); Cibolo networks (https://cibolohealth.com/networks/, https://www.startribune.com/nineteen-rural-minnesota-hospitals-band-together-to-survive/600376647, https://www.fiercehealthcare.com/providers/26-rural-hospitals-launch-partner-network-tackle-operating-quality-improvements-scale). Data grounding: hcai_utilization_comparison.csv (San Gorgonio 27.5% occupancy, LLUMC 109%), Strategic_Analysis_Consulting_Report.md adversarial corrections (winnable pool 2,500-3,100; 40-42% share = +$2-5.5M contribution).

### Regulatory and execution (CPOM / Knox-Keene / OHCA-AB1415 / licensure / CMS rules; leadership, talent, change capacity, timeline slip, concurrent-initiative cap)

**Verdict: VIABLE — confidence 55/100.**

**Fatal flaws:** None that survive the plan's own gating at the planning-case level — but two conditional kill-switches are real and the plan itself admits the first: (1) the $14M philanthropy+PRI raise has zero anchor commitments, and PRIs from health foundations rarely fund private-NFP hospital operating infrastructure (they flow to FQHCs, housing, community clinics); if Tranche A does not fully commit, "the plan does not start" by its own terms. (2) If the co-op must staff out-of-state members from a California clinical labor base, the unit economics likely never clear: CA is not in the NLC or IMLC, so every command-center RN needs an individual license in each member state (8-12 weeks, per-state renewals) and CA-principal-licensed physicians cannot use the IMLC expedited path — while Avel eCare sells the identical service from Sioux Falls (NLC state, ~40-50% lower RN wages). The $500k blended member price at ~26% contribution does not survive that cost stack unless clinicians are domiciled/hired in compact states.

**Required fixes noted:**

- Fix the stale statute in the OB decision: SB 1300 (eff. 1/1/2025) amended H&S 1255.25 to 120-day public notice (not 90), a noticed public hearing within 60 days, notices to contracted Medi-Cal managed care plans and the county board of supervisors, and a community-impact justification. Re-plan the Year-1 defend-or-harvest timeline around 120+ days and budget the hearing/CalMatters-level press cycle.
- Re-domicile the co-op's clinical labor: hire remote RNs/MDs who live in and hold licenses in NLC/IMLC compact states through a non-California staffing subsidiary of the co-op, or partner-white-label for out-of-state modules; otherwise reprice Wave 1 or flip Wave 1 to California-adjacent buyers where CA licensure is the asset, not the liability.
- Stand up a physician vehicle for the co-op itself: a lay cooperative (even hospital-member-owned) cannot employ physicians for tele-hospitalist/tele-consult services under B&P 2400; the plan's friendly PC is scoped to RPM/CCM only. Add a second contracted medical group (or expand the PC with its own management agreement) and cost it — it is in neither the -$1.75M overhead nor the -$1M growth-org line.
- Name the home-health licensure path for the +$1.5M home-based-care line: ~700 SNF-at-home/ED-to-home episodes require a CDPH-licensed home health agency (Title 22) plus payer credentialing; CDPH HHA licensure realistically runs 12+ months. Either acquire/JV with an existing licensed HHA in Tranche B or move this lever from Yr2-4 to Yr3-5.
- Reset the quality gate to the star-rating data lag: current mortality/readmission windows are 3-year lookbacks (e.g., 7/2021-6/2024), so clinical improvements starting Yr1 do not fully enter the overall star until 2-3 annual refreshes later. Underwrite 3 stars at Year 4, not Year 3, and re-time Tranche C and consolidated break-even (Yr5 -> Yr6) accordingly — the gate architecture already tolerates this, the calendar does not yet.
- Resolve the concurrent-initiative contradiction: Years 1-2 as drawn contain 6-7 hospital-side efforts (command-center build, tele-sitting, CDI, supply chain/purchased services, ALOS/flow, unit closure with CNA bargaining, PC/MSO/CIN formation) plus a $6M campaign and $8M PRI cultivation — against a board cap of 2-3 net-new workstreams per 18 months. Formally bundle CDI+flow+supply-chain+revenue-integrity as ONE turnaround-management-office program under an external turnaround partner (this is standard A&M/Kaufman Hall scope), push PC/MSO/CIN formation to months 12-18, and hold home-based care to Yr3.
- De-hostage the P&L repair from the raise: split Tranche A into A1 (~$2-3M: CDI, flow, supply-chain renegotiation — consultant-fee-shaped, partly self-funding within 12 months, financeable with equipment leases and early philanthropy) and A2 ($6-7M command-center fit-out, released on A1 results plus campaign milestones). The strategy's best regulatory feature — everything risky is gated — should extend to its own capital plan.
- Add the member-side regulatory calendar to the sales cycle: each CA district-hospital member's services agreement may itself be an AB 1415 "material change" (MSO-type arrangement) requiring the member's own 90-day OHCA notice, and district hospitals add Brown Act public-board approval; the 15-21 month cycle is right for RCH's side but should explicitly include the buyer's side.

**Panel notes:** This is the rare submission that has already defused the landmines that normally kill California strategies at this committee: no physician employment (friendly PC + MSO under Moscone-Knox; SB 351's hospital exclusion correctly exploited), risk held at Knox-Keene rung 1 (shared savings, no DMHC license — correct per the 2019 global-risk regulation), Title 22 CCR 70217 respected (virtual RNs excluded from ratio math; tele-sitting confined to sitter substitution), CA hospital-at-home booked at $0 (CDPH flexibilities did expire 2/28/2023), the AHCAH 9/30/2030 sunset verified accurate (CAA 2026, signed 2/4/2026), transfer center re-founded at volume-invariant FMV (AKS/Stark-aware), and OHCA/AB 1415 + Corp. Code 5914-5925 priced into the timeline rather than ignored. The load-bearing money (+$21.75M gross) is regulation-light standard turnaround content — supply chain at 0.85% of a $415.7M expense base, CDI at 0.02 CMI points, ALOS 4.5->4.0 against its own 2018 baseline of 3.5 — all inside industry-normal capture ranges, and the failure mode is engineered to degrade to a breakeven core rather than a crater (Tranche C never releases; co-op severable). Execution verdict: a -$16M 2-star independent with a Jan-2026 CEO CAN run this IF the six levers are packaged as one TMO program under an external turnaround partner and the capital plan is split so the P&L repair is not hostage to an unanchored $14M philanthropy/PRI raise. Realistic slip: 12-18 months (CNA bargaining 6-12 months on the two labor levers; star gate lands Yr4 not Yr3; PRI cultivation 18-24 months) — core breakeven Yr4-5, consolidated breakeven Yr5-6, ceiling unchanged. On the lens test (break-even ~3-4 yrs AND the honestly-stated ceiling by ~7-8 yrs): marginal pass — Yr4 core breakeven is inside the window on the plan's own severable $14M hospital-only variant, and the +$1-2M/+$5M ceiling is credible if the fixes land. Confidence held at 55, not higher, for three reasons: the raise has no anchor, the co-op's out-of-state Wave 1 is built on a licensure/wage geography (CA outside both NLC and IMLC) that favors Avel structurally, and the concurrent-initiative math currently contradicts the plan's own governance cap. Verified sources: SB 1300 / H&S 1255.25 (leginfo.legislature.ca.gov bill 202320240SB1300; calmatters.org 2024/09 maternity-care-new-law), NLC membership (ncsbn.org/compacts.page; nurse.org eNLC list), AHCAH extension (congress.gov H.R.4313; ama-assn.org five-year waiver extension; qualitynet.cms.gov acute-hospital-care-at-home).

## A.3 Strategy 3 — Terracina, Priced to Contract + The Independent Alliance

### Financial realism

**Verdict: VIABLE — confidence 60/100.** Fatal flaws: none.

**Required fixes noted:**

- MA-risk attribution (the $9.7M line): booking 100% of the risk-entity margin to RCH operating income contradicts the stated structure (co-capitalized with PHN, professional risk riding PHN's existing RBO). State RCH's economic ownership share and book only that share. At a plausible 50-60% RCH share the success case restates to ~+$15-17M, not +$20M — still passable under the honestly-stated-ceiling clause, but only after restatement.
- Same line is booked at the top of its own ranges: netting $9.7M after $1.2M risk-ops requires 18k lives AND 4.5% of premium simultaneously; midpoint math (17k x $13.5k x 4.25% - $1.2M) gives ~$8.5M pre-split. Rule 1 requires midpoint booking or explicit justification for top-of-range.
- CIN recapture basis is internally inconsistent: per the HCAI patient-origin file the core market is 15,513 discharges and 41-42% share = only ~650-800 incremental discharges/yr, not the "~3,000 x $1,500" stated ("3,000" implies a 56% share). The $4.5M dollar lands inside the honest $2-5.5M range only if contribution is ~$4-7k/case at the honest volume — restate the correct volume x rate pair, and support the above-midpoint booking with signed CIN referral commitments (CAMG/RYMG/PHN LOIs), plus confirm contribution/case is net of variable re-staffing so it cannot claw back the RIF line.
- Book the interest expense on the $15M AR facility (~8-10% distressed healthcare ABL pricing = $1.2-1.5M/yr while drawn, plus unused-line fees) — currently absent from the bridge. With it, FY29 breakeven likely slips 2-4 quarters (still inside the 3-4-yr bar); also show the breakeven date if the gated 340B $2M fails, since FY29 leans on it.
- ASC JV cannibalization ($0.3M) is unverified and likely understated: confirm Arrowhead's current site-of-service mix before booking — RCH performed 5,812 ambulatory-surgery cases in 2024 (HCAI) with US-News ortho recognition, and HOPD-to-ASC rate deltas of $2-3k/case on even 800 migrating cases would erase the line's $1.5M.
- Re-size the gated 340B line to $1-1.5M: DSH eligibility gating is necessary but insufficient — manufacturer contract-pharmacy restrictions (Lilly et al. claims-data mandates, single-pharmacy designations; ~$3.2B/yr industry losses per 340B Report/Becker's) materially erode de novo contract-pharmacy economics in FY28-29 regardless of eligibility.
- Liquidity cushion: cumulative FY27-29 deficits (~$15.5M) + unbooked interest + ~$9M of ungated program capital (ASC $4M, MSO $3M, sleeve $2M) against ~$21M of first-phase sources leaves <$3M headroom; a 15-20% aggregate miss on the FY27-28 cost lines exhausts it. Add a contingency tranche (upsized facility or second RE tranche) or put the MSO buildout behind a cash gate.
- Fence the remaining overlap seams explicitly: non-labor "LOS/throughput" vs the ED status-accuracy line vs bed-consolidation savings — three levers that all monetize shorter stays/fewer occupied beds need a department-level no-double-count map.
- The bridge sums to exactly +$36.0M/+$20.0M across 21 lines — a reverse-engineering tell. Provide a tornado/sensitivity on the six largest lines and state the P50 landing (this recompute: success-case P50 ~+$15-18M after the MA attribution and midpoint fixes; base ~+$7-9M).

**Panel notes:** Recomputed bridge: SHARED +17.2, ALLIANCE +22.4, SLEEVE +0.9, COSTS -4.5 = +36.0 exactly; base case ex-MA = +10.3, ex-340B = +8.3 — internally consistent with the stated +8-10M/+8M plateaus. Verdict logic: breakeven is the harder near-term test and it rests on well-benchmarked, mostly conservatively-haircut cost actions (RIF at 70% capture, ads at 80%, non-labor at 1.2% of opex, rev integrity at 0.75% of NPR); even under a 20% aggregate haircut plus unbooked interest, breakeven lands FY30 — inside the 3-4-yr bar. The +$20M is honestly gated and probability-tagged (40-50%), and the charge accepts an honestly-stated ceiling; however the two basis errors found (MA-risk attribution to RCH vs the co-capitalized structure, and the recapture volume/share inconsistency vs the HCAI file) mean the honest success case is ~+$15-18M as structured, not +$20M — viable only after restatement, hence confidence 60 rather than higher. Genuine credits: rent drag booked at 8% cap, platform prepayments removed as capital, sleeve priced at panel-honest $0.4M, MSO at half Privia's ~$20k/provider EBITDA, hospice per-diem checks vs ~$231 RHC rate, H@H waiver verified extended to 9/30/2030 (de-risks that line through FY30; FY31+ needs a note), AG 5914/5920 sequencing fixed, and margin ceilings respected (4.5% success = bottom of the 4-7% top quartile; ~2% base = typical). Capital sources are individually credible: ABL against $50M+ AR is routine collateral lending even for distressed NFPs; Arrowhead and PHN yes-logic is sound (SB351 hospital exclusion, Optum-alternative positioning) — but PHN's leverage is exactly why the MA margin split must be stated, and the FY27-29 sources/uses cushion is under $3M. Key sources: AMA/CMS QualityNet (AHCAH extension to 2030), Becker's and 340B Report (contract-pharmacy restrictions, ~$3.2B/yr losses), CMS 2025 MA Rate Announcement and KFF (MA payment ~$13-14k/enrollee consistent with the $13.5k assumption); HCAI patient-origin and utilization files on record (15,513 core discharges, 36.8% share, 5,812 AS cases, 56.6% occupancy).

### Market and competitive realism

**Verdict: NOT VIABLE as submitted — confidence 62/100.**

**Fatal flaws:**

- The +$9.7M MA-risk line — the ONLY path to +$20M — books ~100% of the risk entity's 4-4.5%-of-premium margin (17k lives x $13.5k x ~4.25% = ~$9.7M) to RCH's P&L while simultaneously capping RCH's capital at $3-4M and having PHN "co-capitalize." PHN is a 33-physician-shareholder professional corporation whose stated model returns profits to its physician shareholders (web4phn.com/about); no physician-owned RBO hands a hospital partner the full risk margin against half the capital. At a realistic 40-60% RCH equity share, the line is +$4-6M and the success case lands at ~+$13-16M, not +$20M — so the strategy's honestly-stated ceiling is not honest, which is the one thing Rule 4 required of it.
- Systematic top-of-range booking across the three largest Alliance lines, all biased the same direction: recapture books ~3,000 of a 2,500-3,100 winnable pool (~100% capture of the theoretical maximum while LLU defends); the ASC JV assumes Arrowhead routes ~3,200 cases into a 51%-RCH de novo center when Arrowhead physicians ALREADY own Advanced Ambulatory Surgery Center in Redlands (verified via their Sunshine Act disclosure) and Steinmann — a national surgeon-ownership advocate — is already RCH's Spine & Joint medical director, meaning the realistic structure is an RCH minority buy-in worth ~$0.5-0.8M, not $1.5M, and the $0.3M HOPD cannibalization is likely understated; and the risk line takes 18k lives x 4.5% (both top-of-range) when PHN's MA fraction of its ~54k HMO lives is unverified and MA attribution follows PCPs, where PHN's bench may be thin. Corrected, base case is ~+$5-8M and success ~+$12-15M.
- Capacity contradiction between the two biggest levers: consolidating to ~160 staffed beds (the +$4.5M RIF) while recapturing +3,000 discharges adds ~35 ADC at 4.3 ALOS, pushing FY30-31 occupancy to ~88-92% even with hospital-at-home's ~9 ADC relief — above the level where EDs board and transfers bounce. Either recaptured demand physically cannot be served or ~$1.5-2.5M of re-staffing cost re-enters the FY29-31 bridge; the bridge books neither.

**Required fixes noted:**

- Restate the PHN risk-entity economics at RCH's contractual equity share with proportional capital: if RCH wants ~$9-10M/yr of margin it must fund the majority of reserves ($8-10M+, not $2-3M) and absorb matching J-curve risk; otherwise restate the success ceiling at ~+$13-16M and re-answer Rule 4 with that number as the honest ceiling. You cannot cap the downside at $3-4M and keep 100% of the upside — the term sheet the bridge assumes does not exist in the MA-risk market (agilon/Privia/Oak Street splits all run physician-favorable).
- Re-underwrite the ASC line around the verified fact that Arrowhead already owns Advanced Ambulatory Surgery Center (Redlands): model an RCH minority buy-in/expansion or a higher-acuity second site requiring hospital backup, re-price at ~+$0.5-0.8M, and validate cannibalization against Arrowhead's actual current volume at RCH HOPD (Steinmann already directs RCH's Spine & Joint Institute — some of the "new" JV volume is today's RCH revenue).
- Book CIN recapture at mid-range (~$3-3.5M, ~2,000-2,300 discharges): booking ~100% of the re-underwritten winnable pool assumes zero LLU defensive response and perfect CIN referral conversion by FY31; no first-generation CIN achieves that.
- Reconcile the 160-staffed-bed footprint with the recapture volume: either budget staged re-staffing (~$1.5-2.5M/yr in FY29-31, netted against the RIF line) or lower the recapture target; state the resulting occupancy by fiscal year.
- Quantify the Optum retaliation downside before signing Alliance term sheets: Optum owns Beaver (~1,000 staff, Redlands-based) and Optum Care Network-SB/IFMG (230k+ attributed lives) — patients it currently attributes flow into RCH's existing 36.8% share. Model the P&L hit if Optum steers 10-20% of Beaver-derived admissions to St. Bernardine/LLU after the CIN goes public; the current mitigation (speed, SB351, MSO economics) is directionally right but unpriced, and this is a threat to EXISTING revenue, not just to the recapture upside. Note Optum also owns SCA Health and can counter-offer Arrowhead on the ASC.
- Resolve PHN diligence ambiguity before gating any capital: two similarly-named entities (web4phn.com "Physician Health Network" vs physicianshealthnetwork.org), a 33-shareholder governance structure with 7% ownership caps (board approval of a hospital JV is a multi-vote political process, not a bilateral deal), and an unverified MA share of the ~54k HMO lives — 16-18k MA lives may exceed PHN's entire actual MA book, requiring attribution growth from CAMG/RYMG panels that must be separately modeled and timed.

**Panel notes:** This is the strongest market-realism submission of the set in architecture, and it fails only on numbers — all correctable, all biased the same optimistic direction. What genuinely survives attack: (1) the coalition premise is the best-evidenced I have reviewed — CAMG was founded explicitly anti-consolidation, RYMG demonstrably just exited Optum, PHN is physician-owned with Optum as the feared alternative, and Steinmann already sits inside RCH as Spine & Joint medical director, so partner willingness-in-principle is documented, not hoped; (2) demand is sized from on-file data with the correct haircuts (winnable-discharge re-underwriting, 0.40-0.45x commuter haircut, Form 5500 employer census, executive health conceded to LLU); (3) the sleeve is correctly priced as a self-liquidating $0.4M experiment (<$0.5M sunk if platforms won't sign against RadNet/SimonMed — though even 1,500 studies/yr looks 2-3x rich against 600-1,200 pro-rata regional platform members, the >=60% minimum-volume gate absorbs that); (4) the moat is honestly framed as Southwest-not-Tesla, and Kaiser (closed), Optum (the thing being fled, SB351-constrained), and LLU (academic cost structure) genuinely cannot lead this coalition. FY2029 breakeven largely survives the market lens because it is carried by ops levers ($15.2M of shared cost/yield lines) that don't need the market's permission — the market risk to breakeven is Optum steerage shrinking the baseline, which is named but unquantified. The verdict is NOT-viable-as-submitted because the mandate-answering number — +$20M success case — rests on a risk-margin allocation no physician-owned counterparty would sign (PHN's own charter returns profits to its physician shareholders), and the corrected success case (~+$13-16M) was not the stated ceiling. Fix the allocation (or fund the capital that earns it), re-cut the ASC line around the existing physician-owned AASC, book recapture mid-range, and reconcile the bed math — and this flips to viable with an honest ~+$13-16M success / +$5-8M base ceiling, which the board should be asked to underwrite explicitly. Key verification sources: Arrowhead Orthopaedics Sunshine Act beneficial-interest disclosure (arrowheadortho.com/significant-beneficial-interest-sunshine-act/) confirming physician ownership of Advanced Ambulatory Surgery Center; web4phn.com/about confirming PHN's 33-shareholder structure and profit-return-to-physicians model; arrowheadregional.org provider page confirming Steinmann's RCH Spine & Joint role.

### Regulatory and execution (CPOM/Knox-Keene/OHCA-AB1415/licensure/CMS structuring, plus organizational capacity of a -$16M 211-bed independent to execute — leadership, talent, IT, concurrent-initiative cap, realistic timeline slip)

**Verdict: VIABLE — confidence 60/100.** Fatal flaws: none.

**Required fixes noted:**

- Name the ASC JV's licensure and fraud-and-abuse pathway before term sheets. Post-Capen v. Shewry (2007, 155 Cal.App.4th 378), any physician ownership makes the surgical clinic exempt from CDPH licensure — the 51/49 RCH-Arrowhead JV must go the Medicare-certification + accreditation route (H&S 1248 / B&P 2216), not a CDPH surgical-clinic license. Bigger: the AKS ASC safe harbor for hospital/physician JVs (42 CFR 1001.952(r)(4)) requires the hospital NOT be in a position to make or influence referrals — untenable next to a CIN explicitly built to steer referrals to RCH. Falling outside the safe harbor is not per se illegal, but the JV needs a written AKS/Stark analysis, FMV capital contributions, per-capita-ownership discipline, and firewalls between CIN referral management and JV distributions. Currently the plan budgets only the OHCA notice.
- Build a full OHCA/AB-1415 transaction calendar — the plan notices only the ASC JV, but as of 1/1/2026 MSO agreements are themselves noticing events, and the PHN risk-entity JV, the CIN formation, and possibly the sale-leaseback each plausibly qualify as material change transactions for an entity with $407M revenue. A CMIR on any one runs ~7-10 months all-in (90-day notice, 60-day CMIR decision window, 90+30-day review, preliminary report + comment + final report, close 60 days after final report). Pre-file, sequence notices so no single CMIR blocks the FY29 breakeven-critical lines, and add a 2-quarter CMIR contingency to the Alliance timeline.
- Fund the turnaround program office. FY27 as drafted holds 8-9 real workstreams (RIF/Cal-WARN for ~120 FTE, non-labor cost program, revenue integrity, brand exit, stroke-mortality carve-out, Alliance term sheets with 5+ counterparties, AR facility, sale-leaseback + AG 5914/5920 process, venture BD office), not the claimed 4-5. The fix is consolidation plus money: the four cost lines (~$14M of the bridge) are one distressed-turnaround program that needs a named accountable leader and $2-4M of external turnaround/advisory support that appears nowhere in the capital plan or cost lines. Without it, the 70% RIF capture and 1.2% non-labor capture are aspirations, and FY27's -$11M becomes -$13-14M.
- Put CIN clinical-and-financial integration on the critical path with dated milestones. Joint payer negotiation by a CIN of independent groups is price-fixing unless the network is genuinely clinically and financially integrated (FTC/DOJ guidance) — shared data infrastructure, protocols, performance management, and downside exposure typically take 18-24 months to stand up. FY27 term sheets to FY29 recapture revenue implies payer contracts negotiated during FY28; the integration build must start day one and the antitrust opinion must precede any joint rate discussion with commercial plans.
- Re-underwrite the 340B line on the right variable: DSH eligibility is only the first gate; the $2M assumes contract-pharmacy expansion economics that 30+ manufacturers have restricted since 2020 (single-pharmacy designations, claims-data conditions). Model the line net of current manufacturer restriction policies and California's landscape, or cut the gated value to $1-1.5M.
- Name the MA payer counterparty before the FY30 risk gate. Global risk requires an MA plan willing to delegate to the RCH-PHN entity in a market where UnitedHealth owns the dominant delegated network (Optum/Beaver) and will not feed a rival. Realistic counterparties are Alignment, SCAN, Humana, Blue Shield Promise, or IEHP's D-SNP line — at least one LOI should be a gate condition, and the restricted Knox-Keene application (realistically 12-18 months at DMHC, plus TNE build and network-adequacy filings under Title 28 CCR 1300.67.2.2) must start FY29, not at the FY30 gate.
- Name the MSO technology platform partner and re-cut the fee economics. $3M of CIN/MSO buildout cannot build a Privia-grade stack (EHR, RCM, population health, credentialing) for 150 providers; the realistic path is licensing an existing platform, which compresses the assumed ~$10k EBITDA/provider. State the platform, its per-provider licensing cost, and the net margin — and confirm the -$1.5M Alliance overhead line actually covers the 8-12 FTE the CIN/MSO/employer-BD functions need.
- Verify the hospice expansion against California's hospice licensure moratorium (SB 664, H&S 1339.43) with counsel: growth into the Riverside County side of the Pass corridor (Beaumont/Banning) may require service-area or license changes that the moratorium complicates; confirm RCH's existing license geography covers the targeted ADC before booking the $1M.

**Panel notes:** Verdict rationale: this resubmission passes the regulatory lens because every risk-bearing and physician-alignment step sits at the correct legal rung — friendly-PC/MSO (no CPOM violation), SB 351 hospital exclusion correctly used as a recruiting edge, shared savings unlicensed, restricted Knox-Keene only at the gated global-risk step with reserves and PHN co-capital, AG 5914/5920 run on the sale-leaseback with the AR facility sequenced first so survival liquidity never waits on the AG, and philanthropy ring-fenced from commercial exposure. The hospital-at-home contingency I went looking for is moot: the AHCAH waiver was extended 5 years to 9/30/2030 (CAA 2026, Section 6210), covering the FY29-30 line. The sleeve's compliance file (B&P 655.5 anti-markup, AKS/FMV on downstream episodes at RCH's own 36.8% keep-rate, UBIT, ABN) is more complete than most real submissions. On execution, the honest finding is that Year 1 is 8-9 workstreams dressed as 4-5, and the plan funds no turnaround program office — but the breakeven path deliberately rides cost restructuring that needs no license, no partner, and no new market behavior, which is the right design for a distressed independent. Expected slip is 6-12 months (CMIR exposure, RIF ramp, CIN integration), moving breakeven from FY29 (Year 3) to worst-case FY30 (Year 4) — still inside the 3-4 year bar. The +$20M arrives FY33-34 (Year 7-8) only in the 40-50% success case; the base case plateaus at +$8-10M and the strategy says so plainly, satisfying the honest-ceiling clause of the mandate. Viable, conditionally — the eight fixes above are conditions, and the ASC JV fraud-and-abuse structuring plus the OHCA calendar are the two that could actually move dates if ignored. Key verifications: AHCAH extension to 2030 (AMA, CMS QualityNet); Capen v. Shewry ASC licensure gap and mixed-ownership pathway (Nelson Hardiman, Becker's ASC, CDPH FAQ); AB 1415 MSO notice coverage and CMIR timeline of ~7-10 months (HCAI MCN/CMIR page, Ropes & Gray on the first CMIR, Hooper Lundy on AB 1415).

## A.4 Strategy 4 — SilverPass: Earn the Right

### Financial realism

**Verdict: VIABLE — confidence 57/100.** Fatal flaws: none.

**Required fixes noted:**

- ADD DEBT SERVICE TO THE BRIDGE: the $18M receivables-backed facility (plus any accordion draws) carries ~$1.4-1.6M/yr interest at distressed-NFP ABL pricing (SOFR+400-600bps); hospital operating expense includes interest, and no bridge line carries it. Against a 2030 standalone cushion of only +$0.9-1.2M, this alone pushes GAAP break-even to ~2031 (year 5). Either add an offsetting A-block lever or restate break-even honestly at 2031.
- A4 CANNIBALIZATION IS UNDERSTATED UNTIL PROVEN OTHERWISE: -$0.3M net HOPD cannibalization on 2,600 ASC cases requires a case-source split. If a meaningful share migrates from RCH's existing HOPD ortho/spine volume (its US News-ranked franchise, part of 3,871 outpatient surgeries) rather than newly captured Arrowhead volume, lost hospital contribution at $1,500-3,000/case runs $1.5-3M and flips A4 negative. Publish %-new-capture vs %-migrated with Arrowhead's current site-of-service data before committing the wing.
- PROVE NO A1/A2 LABOR DOUBLE-COUNT: the ALOS-reduction savings (3,842 bed-days x $350 = $1.3M, mostly variable nursing hours) and the A1 premium-labor line ($4.5M) draw on the same labor baseline. Publish a single combined labor bridge; exposure ~$0.5-1M.
- STATE THE BASELINE-DRIFT ASSUMPTION: the bridge holds -$16M flat 2026-2030. If wage inflation outruns rate updates by ~1%/yr (typical for a distressed CA hospital with Medi-Cal-heavy payer mix), ~$3-4M/yr of drift accumulates by 2030 that the $10M PI must absorb on top of its target. Declare whether A1 is net-of-drift; if not, name the additional levers or restate the standalone break-even year.
- RESIZE B6: $0.7M (~4 FTE) cannot staff SB 351 non-delegable authority for real across two risk books plus a friendly PC (PC-employed coding leadership, payer contracting, RKK/DMHC compliance, delegation oversight, independent actuarial). Realistic load is $1.2-1.8M; at $0.7M the plan repeats the on-paper-compliance pattern it claims to reject.
- PRICE THE PARTNER'S YES: at plan of record the operator's $30M buys ~$3.4M/yr fee revenue (perhaps $0.7-0.9M fee margin) plus 80% of $1.3M B1 net = ~$1.8-2M/yr, a ~6% cash yield with 1x return-of-capital taking well past a decade unless gates fire. Post-Cano/CareMax no operator underwrites that on the central case. Put G6 replication economics INTO the term sheet (warrants, replication royalties, or ROFR pricing) or treat the mid-2027 no-partner sensitivity as the base case and say so to the committee.
- RESIZE THE HOSPITAL BRIDGE: stated $39M vs ~$34M cumulative losses leaves ~$5M cushion, but with ABL interest, PI contingency fees (~$2-3M one-time on $10M savings), and any baseline drift, cumulative 2026-2030 cash need is $37-42M. Size to ~$45M or pre-commit hospital-side accordion access before signing, not after a covenant scare.

**Panel notes:** The arithmetic survives recomputation, which is rare in this exercise: -16 + 22.1 firm = +6.1M (stated); +14.0 gated = +20.1M ~2040 (stated). No structural double-counting found — B2/B4 hospital-side shifts are correctly netted against the $2.53M/$3.8M these lives already generate in the -16M baseline, and the B1/B3 transfer-price architecture (internal Part A booked as claims in the risk book, contribution booked hospital-side only as increment) is coherent, though it needs an audit-grade transfer-pricing policy to stay clean. Unit economics sit at or below published benchmarks across the board: $1,075 PMPM vs ~$1,354 2026 MA average payment (CMS/MedPAC), $1,700/patient center contribution vs Oak Street's never-realized ~$2,456 embedded ($7M/mature center per CVS acquisition materials), 28% ASC EBITDA in the 25-35% band, institutional cap at 3% (low end of 3-6%), PI at 2.4% of expenses (mid-band distressed), hospice 13.5% in-band. The J-curve is honest (partner-funded in cash, 4-5yr cohort maturity, upside-only year 1, stop-loss on both books) and the failure comps (agilon -$263M 2023, Oak Street sold/impaired, Cano and CareMax Ch.11) are accurately cited. VERDICT LOGIC: this strategy passes ONLY via the honestly-stated-ceiling clause. It does not and says it does not reach +$20M in any credible window; the committee is explicitly told not to fund on the 2040 full-gated case. My corrections (~$3-4.5M: ABL interest, A4 cannibalization, A1/A2 overlap, B6 resize) compress the plan of record to roughly +$2-4M by 2035 and slip standalone GAAP break-even to ~2031 (year 5, substantively break-even 2030) — at the outer edge of the ~3-4yr leg but within its tolerance given the downside is non-catastrophic (no partner = a break-even hospital, not an agilon-style blowup). Confidence is 57, not higher, for three reasons: (1) the $10M turnaround is mid-benchmark but at a hospital with no demonstrated extraction record and a deteriorating baseline (-8.6M FY24 to -16M current), (2) the partner-yes case is the weakest link and Block B is 4.9 of the 22.1 firm points, (3) both mandate-clock legs clear only with the tilde's latitude. Fund it as what it says it is — a break-even restructuring plus a severable option — not as a path to +$20M.

### Market and competitive realism

**Verdict: VIABLE — confidence 55/100.** Fatal flaws: none.

**Required fixes noted:**

- Publish the 4,000-life composition and audit RYMG's actual MA panel before underwriting B1. The 7.5-8.5k non-Kaiser pool reproduces from the demographics file (23,937 corridor seniors x 55-60% MA x 35-45% Kaiser), but ex-UHC the contestable pool is only ~4,500-6,000 (Beaver/UHC plausibly holds 30-40% of non-Kaiser MA), making 4,000 lives a 65-90% capture rate — impossible de novo. Underwrite 4,000 only if signed RYMG/CAMG panels carry >=60% of it at close; otherwise base-case the plan's own 3,000-life downside and restate the ceiling at ~+$4.5-5M.
- Model the Optum counter-launch, not just the Optum outbid. UHC does not need RCH's beds — it internalizes premium at the plan level, so a Beaver-anchored senior-clinic build in Redlands/Yucaipa (Optum's standard response to losing RYMG) compresses the contestable pool from the UHC side exactly as Kaiser compresses it via AEP. Carry a combined 2-3%/yr pool-compression sensitivity, not Kaiser's 1-2% alone.
- Correct the PCP arithmetic in the risk register: 519 of 839 is ALL dominant-network corridor PCPs (Kaiser + LLU + Optum + county + Dignity per independent_provider_analysis.md), not Optum's count — restate Optum-specific control before this goes to a board. Add UHC commercial-contract retaliation against the hospital as a named risk with the mutual-hostage mitigation stated (UHC needs the only corridor hospital in-network for ESRI/RUSD-type employers), not assumed.
- Name three real operator counterparties with CA delegated-MA (Knox-Keene RBO) infrastructure. Wellvana/Honest are MSSP/ACO-REACH enablers with no California delegated-risk stack; the realistic list (CareMore-alumni platforms, Alignment-adjacent operators, distressed P3/NeueHealth assets) is thin. If fewer than three credible names respond to a teaser by Q1 2027, pull the $5M development fee from the liquidity bridge now — it is sensitized, but the bridge cushion is only ~$5M.
- State the baseline secular-decay assumption under Block A: discharges are -31% since 2018 and the prior review documented LLU expanding ambulatory into Redlands. Break-even 2030 rests on a ~$1.2M cushion; show it net of 1-2%/yr core contribution erosion or explicitly defend zero decay.
- Make the Arrowhead term sheet an A4 gate: SCA/USPI/Tenet or LLU can outbid for the IE's largest independent ortho group (27+ surgeons), and the delicensed-wing conversion must clear CDPH freestanding-ASC licensure and payer freestanding-rate treatment before the $1.2M is booked.
- Add the demand-side echo of OB closure to the Phase-0 gate: the prior adversarial review's own finding — harvesting OB forfeits the maternity first-touch that feeds family commercial lives — hits A5 recapture and the community-trust brand the senior clinics depend on. Quantify it alongside the 340B/DSH model, not just the regulatory process.

**Panel notes:** This is the rare strategy where the demand math traces to the data instead of past it: the contestable MA pool reproduces from service_area_demographics.csv; recapture is booked below the midpoint of the re-underwritten $2-5.5M band; the commuter 0.40-0.45x haircut is respected (Block B is residence-based seniors, correctly); the Pass, duals, Hemet, and replication are all booked at $0 behind executed-agreement gates; and the quality claims (2-star overall, stroke as the only worse-than-national mortality flag among 21 hospitals, 75% recommend 4th of 21, sepsis 5th of 21) all verify against hospital_care_compare_analysis.md. The moat is honestly split, and the load-bearing element — sole non-Kaiser acute hospital in the Redlands-Yucaipa-Calimesa corridor at 56.6% occupancy, giving internalized Part A at marginal cost — is verifiable in the HCAI utilization data and is a genuine structural difference from every dead senior-risk comp. Competitor responses are mostly pre-priced: Kaiser AEP encroachment (G3 gate), the RYMG race vs Optum/Astrana (launch precondition with walk-away), LLU's 109% occupancy paralysis and SGMH incumbency (Pass at $0), SB351 dynamics. Two market gaps keep confidence at 55: (1) the ex-UHC reading of the 4,000-life base case implies a 65-90% capture of a ~4.5-6k pool — survivable only via documented RYMG panel conversion, which the plan gates but does not size; (2) the unmodeled Optum clinic counter-launch, which attacks the pool upstream where RCH's bed moat is irrelevant. Break-even 2030 (year 4) is credible on this lens because Block A is largely market-independent, though the ~$1.2M cushion is thin against secular decay. The honestly-stated ceiling (+$6.1M, 2034-35 — years 8-9, marginally past the window) is a conjunction of contested events at roughly coin-flip-to-60% odds, with graceful degradation to +$4-5M; the severable architecture means Block B failure strands the upside but not the entity. On the mandate itself the strategy is candid: no Tesla pull-away, no $20M inside any credible window — viable on its stated ceiling, not on the client's stated ambition.

### Regulatory and execution (CPOM/Knox-Keene/OHCA-AB1415/licensure/CMS structuring, plus whether a -$16M 211-bed independent can actually execute this on the stated clock)

**Verdict: VIABLE — confidence 60/100.** Fatal flaws: none.

**Required fixes noted:**

- Add the OHCA/AB 1415 transaction calendar the strategy currently omits entirely: the NewCo/MSO formation (AB 1415 explicitly reaches MSOs and newly created entities), the ASC JV, the $12M MOB sale-leaseback, the SGMH MSA (G1), and the IEHP delegation (G2) are each plausibly "material change transactions" requiring 90-day advance notice for closings on/after 4/2/2026, with CMIR exposure adding months if triggered. File notices in parallel with Phase 0 or the 2029/2030 clinic dates slip by construction.
- Extend the DMHC adverse-determination contingency from B3 to B1. The clinic global-risk book equally requires restricted Knox-Keene or a 1300.49 exemption — 28 CCR 1300.49 captures ANY entity taking professional + institutional risk, not just the hospital-held institutional line. Pre-structure the fallback (professional-only capitation at the friendly-PC as an RBO under 28 CCR 1300.75.4, hospital-held institutional capitation as a separate contract — noting DMHC may look through paired arrangements) and capitalize NewCo to RKK tangible-net-equity standards from the $30M raise so an adverse ruling defers dollars, not the launch.
- Correct the Corp. Code 5914-5925 scope. AG review does not attach to the OB closure itself (RCH is independent with no prior AG conditions; SB 1300's 120-day notice + hearing is the binding process, correctly cited) — it attaches to the $12M MOB sale-leaseback and the delicensed-wing contribution to a for-profit ASC JV, both transfers of a material amount of NFP health-facility assets against a $57.5M net-asset base. Budget 60-105+ days plus a public meeting per transaction, and sequence them away from the OB-closure news cycle the plan already fears for philanthropy.
- Reprice B6. ~4 FTE / $0.7M understates the SB 351 non-delegable stack (PC-held coding integrity, payer-contracting authority, clinical policy) PLUS delegation oversight, stars/HEDIS operations toward the CMS 3-star gate, and actuarial audit. A VBC president alone is $400-600k; market-real total is $1.5-2.5M at maturity for a distressed IE independent recruiting against Optum comp. Restate B-block net or show a legal opinion on exactly which functions the 6.5% platform fee lawfully covers under SB 351.
- Enforce the concurrency cap honestly. Wave 1 as drawn is 6-7 workstreams (PI turnaround, delicensing + seismic re-scope, OB Phase-0/SB 1300 process, ASC development, two financings, RYMG race + operator courtship + DMHC filings) on a C-suite that has never run one, with a CEO in seat since Jan 2026. Either count financings and Phase-0 option work inside the four-major cap or fund a dedicated transformation PMO in the bridge liquidity.
- Complete ASC-conversion diligence before banking the $4M shell appraisal: CMS ASC distinctness/co-location separation requirements (42 CFR 416 — the ASC cannot share space with hospital operations), CDPH/HCAI conversion of the wing out of GACH licensure concurrent with the seismic re-scope, and ASC safe-harbor one-third tests for the Arrowhead physician investors.
- Rebase the calendar to reality: it is July 2026 and every 2026 milestone (Phase-0 340B/DSH model, RYMG term sheet, operator development-fee signing, OB decision) is already half-year compressed. Show H2-2026 start with 2031 standalone break-even as the central case and 2030 as the stretch case — the plan's own risk section already half-admits this.

**Panel notes:** VERDICT RATIONALE (narrow pass). This is the best-structured strategy I have reviewed on this lens, and I default-skeptically checked its statutes: SB 1300 (Cortese 2024, H&S 1255.25) verified — 120-day notice + public hearing for perinatal elimination, correctly used as a gate; 28 CCR 1300.49 verified — global risk requires full/restricted KK or exemption, and the reg gives DMHC a 30-day determination clock, so the concurrent-filing design is sound (the 18-24-month RKK fallback is the right downside); SB 351 hospital exclusion is real and the plan correctly does NOT rely on it for the PE-backed partner MSO — B6 keeps non-delegable functions at the friendly-PC, which is exactly right; CPOM handled via friendly-PC+MSO, no employment assumed; B&P 16600/Ixchel handled with equity instead of exclusivity; hospice JV FMV/AKS-flagged; no MA plan above passive 9.9% avoids the full-KK trap. The architecture — severable option, signed gates, downside = a funded break-even hospital, pre-agreed banker-run affiliation trigger at 2029 OI < -$4M — is how you let a weak-execution organization attempt this without betting the license. On the mandate test: break-even 2030 standalone (year 4, credible with the 1-year slip I would underwrite) and the honestly-stated ceiling of +$6.1M by 2034-35 (years 8-9) is achievable if the fixes above land; the strategy itself tells the committee not to fund the ~2040 +$20M full build, which is the correct posture. WHY ONLY 60: three regulatory calendar gaps (OHCA absent entirely, AG 5914 mis-scoped, B1 licensure contingency missing) and one structural understatement (B6) are all fixable on paper but each costs 3-9 months, and the binding constraint is not law — it is that wave 1 loads 6-7 majors onto a distressed C-suite in a compressed half-year 2026. Execution slip of 12 months on break-even and 12-18 months on plan-of-record is my central case; the plan survives it, but the committee should fund it as a 2031/2036 plan, not 2030/2035. Sources: https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202320240SB1300 ; https://calmatters.org/health/2024/09/maternity-care-new-law/ ; https://www.law.cornell.edu/regulations/california/28-CCR-1300.49 ; https://www.sheppard.com/insights/blogs/knox-keene ; https://hooperlundy.com/sweeping-changes-to-knox-keene-licensing-requirements-coming/ ; https://www.leechtishman.com/insights/blog/new-dmhc-regulation-expands-knox-keene-licensure-requirements/ ; on-file brief california_regulatory_requirements.md (CPOM B&P 2400; SB 351; Corp. Code 5914-5925; AB 1415/OHCA; 28 CCR 1300.75.4).

## A.5 Strategy 5 — Mothership & Fleet 3.0: Turnaround First, Buy Don't Build

### Financial realism (skeptical IC reviewer: bridge arithmetic, unit economics vs. published benchmarks, capital sizing/fundability, J-curve honesty, margin ceiling)

**Verdict: VIABLE — confidence 60/100.**

**Fatal flaws (both conditional, resolvable at Gate Zero):**

- CONDITIONAL-FATAL — liquidity understatement: the stated "peak external liquidity need ~$10-12M" contradicts the plan's own loss sequence. Cumulative Years 1-4 cash needs are ~$44-47M (op losses Y1-Y3 of $20.1M per the plan's own -$10.8M/-$7.5M/-$1.8M path + $8M one-times + $16-19M equity checks) against identified external sources of only $24-29M (MOB $12-14M + philanthropy $5M + recycled JV distributions $3-4M + bridge $4-6M). The residual $15-20M implicitly draws on existing unrestricted cash that is UNVERIFIED — the plan itself makes the 13-week cash forecast and days-cash disclosure preconditions, i.e., admits it does not know. A hospital burning $16M/yr with $57.5M mostly-illiquid net assets and ~$170.5M liabilities (FY2024 990: total assets $228.0M) may not have it. If unrestricted cash is under ~$15-20M AND the master-trust indenture bars the bridge, RCH hits a cash wall in Year 2 before the turnaround matures — the pre-agreed fallback (30% flagship, defer multi-spec) shrinks the ask but does not close a gap that size. Verifiable in 90 days at Gate Zero; fatal only if the cash forecast fails.
- CONDITIONAL-FATAL (universal, correctly flagged in-plan): 2030 seismic compliance is an unsized senior claim; the AB 869 delay window closed 1/1/2026 with RCH's filing status unknown. An unfunded need >$25M consumes every identified capital source and invalidates the Year-4 break-even. The plan gates on it (30-day confirmation + engineering estimate), which is the right treatment, but until sized the break-even carries an asterisk. This kills every strategy equally, not just this one.

**Required fixes noted:**

- PRICE SB 525 — the largest unpriced line in the bridge. RCH almost certainly sits in the standard tier: $21/hr now, $22/hr from 6/1/2026, then a STEP TO $25/hr on 6/1/2027 — dead center in the break-even window (plan Years 1-2). On a ~$415.7M expense base (~55% labor), lifting the sub-$25 workforce plus wage-compression ripple plausibly costs $2-4M/yr run-rate by FY2028, eroding 17-34% of the $11.7M restructuring line; the +$2.0M wave-4 trigger only partially covers it. First step: verify whether RCH qualifies for the "independent hospital with elevated governmental payor mix" slow tier ($18/hr flat to 2033) — its Medi-Cal-heavy San Bernardino draw makes this checkable in a week and it changes the answer materially. If standard tier, base-case break-even slips toward Year 5 unless wave-4 is pre-committed rather than contingent.
- RESTATE sources-and-uses: publish the full 4-year cash flow (op losses + one-times + equity checks vs. all sources by year) with a days-cash-on-hand floor covenant, and correct the "peak external need ~$10-12M" claim, which is only true if RCH holds >=$20M unrestricted cash today. If it does not, move the fallback (flagship at 30% ~$6.5M, multi-spec deferred) INTO the base case and re-sequence Tranche 2.
- Label fix: the cost program is 2.81% of the $415.7M expense base ($11.7M), not "3.0%" ($12.47M). Trivial but an IC will catch it; restate as 2.8% or add $0.75M of identified actions.
- Acknowledge the minority-multiple premium explicitly in the flagship deal memo: ~7x EBITDA is control-level pricing (VMG Health 2025/2026: control 7-8x, single-specialty 5-8x, minority interests normally priced 20-40% below control). The ~$8.6M check embeds a ~$2-3M strategic premium vs. market minority pricing — defensible as the liquidity pitch that wins against SCA/Optum, but it must be board-visible and inside the pre-set walk-away price, and the FMV opinion must support it for AKS purposes (an above-FMV buy-in from a referral-source physician group is exactly what a qui tam relator looks for).
- Turnaround slippage tolerance: at the break-even point ~95% of the swing is cost restructuring + RCM. Industry experience is 60-80% of identified savings stick net of backfill. The plan survives ~88% realization; below that, break-even is Year 5. Pre-commit (not just pre-plan) the wave-4 trigger and tie Tranche 2 release to a Year-2 realization test (e.g., >=85% of waves 1-2 run-rate verified).

**Panel notes:** RECOMPUTATION — the bridge is arithmetically clean, the first in this strategy family to be so. Phase I-II: positives 11.7+3.5+2.0+1.5+1.0+0.8+2.2+1.0+1.0+0.6+0.2 = +25.5; negatives -3.5-2.0-2.4 = -7.9; net +17.6 as stated; -16.0+17.6 = +$1.6M at Year 7. Phase III conditional: +7.7+9.2+2.0+2.0-2.5 = +18.4; total +36.0 → +$20.0M at Year 13-15, correctly labeled option value. Every sub-line multiplication checks (flagship: 700x$10.8k + 500x$12k + 4,300x$2.6k = $24.7M x 28% = $6.9M, -$1.5M D&A/interest = $5.4M x 40% = $2.2M; GI: 8,500x$1,150 = $9.8M x 34% = $3.3M → $1.0M at 40%; multi-spec, Pass, imaging all foot). NO double-counting found: recapture (inpatient surgical) / medical retention (ED-medical) / CMI (explicitly netted) / cannibalization (outpatient electives) sit on disjoint volume; RCM is yield-only; employer line is separate revenue. Equity-method treatment and JV-level debt are handled correctly — JV debt is genuinely non-recourse and lender-fundable at 1.8-2.1x center EBITDA. UNIT ECONOMICS vs. verified benchmarks: flagship blended ~$4.5k/case vs. $6,419 national ortho ASC average and GI $1,150 vs. $1,362-1,420 (HST Pathways 2024) — below national, conservative; CY2026 ASC update +2.6% (CMS final rule) supports the ~$9,393 TKA floor; facility EBITDA 26-34% sits inside the 25-35% band, below USPI's ~40%; RCM at 0.85% of net revenue is below the 1-3% distressed range; imaging honestly ~zero after lease interest. Break-even phasing is internally consistent: my independent Year-4 build sums to ~+$15.7-16.0M of swing online — Year 4 holds on paper, Year 3 turnaround-standalone holds if cost run-rate lands. J-CURVE HONESTY: exemplary — one CMIR in base, cannibalization stress tested, GI line deletes on a gate, rate-delta stressed to zero, +$20M explicitly disclaimed as Year 13-15 scenario. Margin claims are below industry ceilings (0.4% consolidated Year 7 vs. 1-3% community-hospital typical), i.e., no overclaim. THE HONEST READ: this is a $24-27M turnaround-plus-option-purchase producing +$1-2M by Year 7 — it meets the lens test only via the "honestly-stated ceiling" clause, and the fleet is net-NEGATIVE ~-$1.4M in the bankable window before the counterfactual credit (income +$5.0M vs. -$3.5M cannibalization, -$2.0M overhead, ~-$0.9M financing); the plan admits this. Viability is contingent on two Gate Zero verifications (unrestricted cash >= ~$20M; seismic < ~$25M unfunded) and on pricing SB 525; note the turnaround-only fallback still clears break-even Year 3-4 on just Tranche 1 (~$15-16M, coverable by MOB + philanthropy alone), which makes the break-even commitment — though not the fleet — robust to the platform failing entirely. Sources: https://www.cms.gov/newsroom/fact-sheets/calendar-year-2026-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center ; https://ascnews.com/2024/10/with-an-average-net-revenue-per-case-of-6419-orthopedics-again-proving-profitable-for-ascs/ ; https://www.hstpathways.com/specialty-data/gastroenterology/ ; https://www.dir.ca.gov/dlse/Health-Care-Worker-Minimum-Wage-FAQ.htm ; https://www.lcwlegal.com/news/new-law-sb-525-sets-higher-minimum-wages-for-certain-health-care-employees/ ; https://focusbankers.com/ambulatory-surgery-center-ebitda-multiples/ ; https://vmghealth.com/insights/blog/selling-your-asc-in-2026-key-valuation-drivers/ ; data file rch_financials_utilization.csv (FY2024: $407.1M rev / $415.7M exp / $228.0M assets / $57.5M net assets).

### Market and competitive realism

**Verdict: VIABLE — confidence 70/100.** Fatal flaws: none.

**Required fixes noted:**

- Reconcile the flagship capacity contradiction: AASC is a verified 6,300 sq ft, 3-OR center (aascsurgery.com; US News ASC profile). The 5,500-case/$24.7M maturity model (700 joints + 500 spine) cannot fit in 3 ORs (~1,830 cases/OR/yr with long ortho cases); the $8M "expansion" NewCo debt implies new ORs, which contradicts the "no new ORs in the bankable window" basis for cutting cannibalization from -$5.5M to -$3.5M. Either cap flagship maturity at ~3,600-4,200 cases (RCH share falls ~$0.6-0.9M; Year-7 P&L drops toward +$0.7-1.0M) or restore -$5.5M-class cannibalization from the year expansion ORs open and re-run the Year 4-5 break-even sequence.
- Label the flagship's $4.2M "existing EBITDA" as unverified until diligence: no financials for this private center exist anywhere in the data room; the entire ~$29M EV, the ~7x price, and the +$2.2M line derive from it. Add an EBITDA-miss scenario (e.g., actual $2.5-3M) showing the re-priced check and reduced RCH share, so the walk-away price is set against a distribution, not a point estimate.
- Recast the anti-steerage contracts with IEHP, PHN, PromiseCare, and All United from "Tranche-0 conditions precedent" to negotiated objectives with a defined proceed/no-proceed test. A public Medi-Cal plan (IEHP) and risk-bearing IPAs almost never sign steerage guarantees as pre-conditions; as written, the gate either stalls the entire platform or gets quietly waived — both worse than an honest partial-attribution assumption.
- Add stroke/Primary Stroke Center certification and star-rating remediation to the COMMITTED turnaround (it is ranked #2 of 23 in the client's own service-line scorecard, cheap, and "fixes a live quality liability AND stops EMS routing strokes to LLU"). A 2/5-star hospital with the market's only worse-than-national stroke mortality, simultaneously announcing bed closures and OB right-sizing, faces a reputational demand headwind that directly threatens the +$2M recapture, +$1.5M retention, and the 61,472-visit ED funnel the moat section relies on — and undercuts the $5M "keep care local" philanthropy campaign.
- Pressure-test the 7x walk-away against live control bids: USPI/SCA and PE pay 8-10x+ for marquee ortho centers with a 27-surgeon captive funnel; state the maximum defensible multiple for a 40% MINORITY stake (with explicit minority-discount logic and the surgeon-autonomy premium quantified) so the board's walk-away is not set below the market-clearing price by construction, handing the asset to SCA 1.5 miles away.
- Time-decay the Phase III option honestly: Optum has already absorbed Beaver, PrimeCare, and IFMG; the 188-group independent bench (and the corridor surgeon supply Phase III-B needs) shrinks every year. An option exercisable Years 8-15 against an acquirer running at Optum's pace is a wasting asset — pull the corridor TAM study and anchor-relationship work (CAMG/RYMG/Arrowhead orbit, PHN) into Years 1-2 and state an explicit option half-life.

**Panel notes:** VERDICT LOGIC ON THIS LENS. (1) Demand is real and data-sized, not hoped: recapture is held at the adversarially re-underwritten midpoint (+$2M of the $2-5.5M band from the 36.8%-share/70%-locked leakage analysis); retention rides RCH's own geographically-driven ED volume (61,472 visits, #2 ED magnet in the service area); elective migration is secular and documented (RCH outpatient surgery already exceeds inpatient). The two ASC anchors verify as real assets (AASC at Arrowhead Ortho's own HQ address; Inland Surgery Center = SCA-managed incumbent). (2) Competitive response survivability is the strategy's strongest feature — by design, every contest it can lose has a priced fallback that preserves break-even: AASC auction lost -> Tranche-1-only, Year 3 break-even stands; GI seller takes a PE bid at 7-9x -> line deletes cleanly; employers don't switch -> $0.8M line, immaterial. The committed break-even engine (cost restructuring + RCM = $15.2M of the $20.5M turnaround swing) is essentially market-risk-free; Kaiser is irrelevant (closed network), DTC players are irrelevant (this is not a DTC play), and Optum steerage is diversified via Arrowhead's own 11-office funnel and the ED. (3) The moat is honestly disclaimed: pre-close there is NO moat — the 90-day AASC window is a naked auction against SCA (20-yr incumbent, and Kaiser contracts into its center) and LLU (Barton Rd surgical hospital); post-close, surgeon-equity gravity + buy-sell economics is a real switching-cost lock given B&P 16600's non-compete ban, and the RYMG-fled-Optum precedent makes the local-independence pitch credible with the actual customer (surgeons). (4) Customers switch: patients already have; surgeons plausibly (liquidity + retained 60% control vs SCA strings vs LLU absorption); employers weakly (correctly sized small and deferred). CAVEATS THAT CAP CONFIDENCE AT 70: the flagship capacity/cannibalization contradiction (fix #1) is the closest thing to a fatal flaw — if reconciled unfavorably, combined break-even slips to Year 5 per the strategy's own stress and Year-7 P&L approaches zero; break-even-in-window then rests entirely on the Year-3 turnaround-standalone claim, which is a cost story, not a market story, and holds. The +$20M endpoint fails the client's Tesla mandate on this lens and the strategy says so plainly — Year 13-15 scenario only, against an independent-physician bench Optum is actively depleting (fix #6), so treat Phase III-B as decaying option value, not a plan. Viable = TRUE on the structured test (break-even Year 3-4 credible; honestly-stated ceiling of +$1-2M by Year 7 credible and robust to competitor response), not on the client's stated ambition. Sources verified via WebSearch: aascsurgery.com; health.usnews.com/best-ascs/area/ca/advanced-ambulatory-surgery-center-redlands-A9018362; inlandsurgerycenter.com; healthy.kaiserpermanente.org/southern-california/facilities/inland-surgery-center-lp-429449.

### Regulatory and execution (CPOM/Knox-Keene/OHCA-AB1415/licensure/CMS; leadership, talent, change capacity, concurrent-initiative cap)

**Verdict: VIABLE — confidence 62/100.**

**Fatal flaws (one, conditional):**

- CONDITIONAL KILL, pending Gate Zero: RCH (211 beds, non-rural, non-district) appears INELIGIBLE for the AB 869 seismic delay window that closed 1/1/2026 (PIN 80 eligibility = <=50 beds, rural, critical access, Distressed Hospital Loan recipients, district hospitals) unless it quietly took a DHLP loan. The strategy's "filing status unknown" understates the risk: the likely reality is a hard 2030 SPC-2/NPC deadline with no delay path. If the engineering estimate shows >$25M unfunded need, the plan's own trigger freezes Tranche 2 and forces the affiliation track — capping this strategy at its turnaround core. Verified via HCAI PIN 80 and CHA guidance; this is the only finding that can kill the platform outright, and the plan at least pre-wires the off-ramp.

**Required fixes noted:**

- Re-scope the anti-steerage contracts with IEHP/PHN/PromiseCare/All United: as EXECUTED Tranche-0 conditions precedent they are commercially improbable (a 2-star, -$16M hospital has no leverage) and anti-steering terms are Sutter-settlement-toxic in California contracting. Downgrade to network-participation / no-adverse-tiering confirmations as Tranche-1 objectives, or the condition precedent blocks the platform on Day 1.
- Rewrite the seismic gate to assume AB 869 INELIGIBILITY, not "filing status unknown": commission the SPC/NPC engineering assessment immediately as the true Gate Zero and underwrite the hard 2030 deadline; the 30-day confirmation should be of building ratings and cost, not of a filing that probably could not have been made.
- Price the ASC regulatory conversion at buy-in (currently unpriced): post-Capen v. Shewry, CDPH cannot license surgical clinics with physician ownership, so the hospital-physician JV operates on Medicare certification + accreditation — the recap triggers a Medicare CHOW (855B) and, critically, change-of-control/assignment clauses in the centers' commercial payer contracts. The 7x is being paid for an EBITDA whose commercial rates can reprice at close. Add contract-assignment diligence to the 90-day window plus a purchase-price adjustment mechanism.
- Resolve the AKS/FMV tension at the heart of the Track-B pitch: "cash today at a FULL multiple for a MINORITY stake" paid to referral-source physicians is, on its face, above-FMV consideration (minority interests normally price at a discount to control multiples). The FMV opinion must support 7x-for-40% on standalone finance grounds (expansion capital, buy-sell rights, complex-case backstop) or the price comes down and the "winnable pitch" gets re-tested at term sheet — before capital commits.
- Hard cash-gate the GI equity check: Year-1 identified sources (~$5M philanthropy pledged-not-collected + $4-6M gated bridge) do not cover Tranche 1 ($15-16M); MOB proceeds arrive Year 2 only after AG pre-clearance + OHCA notice. Release the $6.5M GI check only after bridge or MOB proceeds are banked, else a -$16M-burn hospital is writing checks against un-cleared gates.
- Count the Tranche-0 gate work inside the bandwidth cap: the "4 Year-1 workstreams" framing excludes 8+ gating items (indenture review + covenant letter, 13-week cash forecast, seismic assessment, DMHC counsel letter, payer confirmations, GI fallback diligence, corridor TAM study, AG pre-clearance prep, board walk-away pricing) that all land on the same CFO/GC/CEO. Either staff a dedicated PMO inside the $8M one-time budget or add the realistic 6-12 months of slip to the Tranche-1 sequence explicitly (combined break-even Year 4 becomes Year 4-5).
- Re-confirm "connected transaction" aggregation under the final AB 1415 regulations (still in proposal as of June 2026, comments closed 6/11/26) before fixing the GI -> flagship -> multi-spec deal calendar: if OHCA aggregates the sequenced deals, the single-CMIR base case may understate to two, which the plan currently carries only as stress.

**Panel notes:** This is the cleanest regulatory architecture in the option set and it verified well under attack. CPOM: no physician employment anywhere; ASC JVs are facility ownership, not the practice of medicine; SB 351's PE restrictions exclude hospitals (confirmed in the regulatory brief on file). Knox-Keene: correctly deferred — shared-savings/direct contracts need no license, and the DMHC counsel letter on ERISA flat-rate bundles is properly a condition precedent (case rates for self-provided services generally fall outside licensure, but the letter is the right discipline). Stark/650.01: the wholly-owned imaging fix is correct — referring-physician equity in an imaging JV has no ownership exception. OHCA: the +6-11-month single-CMIR assumption verified against the actual statutory clock (60-day decision + 90-day review +30 extension, tollable, + comment/final + 60-day post-final wait = ~8-9+ months); pricing one CMIR into the BASE case is something no prior version did. Execution: the inversion is what makes this pass the lens — break-even Year 3-4 is carried entirely by Engine A (restructuring at 3.0% of expenses with $8M one-time costs priced, vendor-executed RCM at 0.85% of NR), which needs no deal, no partner signature, and no new financing structure; every regulatory failure mode of Engine B degrades to a fallback that still clears break-even. Track-B (buy existing EBITDA) also removes the construction/licensure J-curve that made v2.0 unexecutable. Remaining execution honesty gaps: the Tranche-0 gate stack is undercounted against the 4-workstream cap, the anti-steerage conditions precedent are not gettable as written, and Year-1 cash sources lag Tranche-1 commitments. Verdict: viable ON ITS HONESTLY-STATED CEILING (+$1-2M by Year 7; +$20M is explicitly Year 13-15 option value, not underwriting) — the schema's ceiling clause is satisfied because the plan states it plainly and the committed number is credible on this lens after the fixes. The one thing that can still kill it is the seismic wall, and the likely AB 869 ineligibility makes that worse than the strategy admits — but that risk is existential to every strategy for this asset, and this is the only plan that pre-wires the affiliation off-ramp. Sources: HCAI PIN 80 (hcai.ca.gov/document/pin-80-seismic-compliance-plan-and-ab-869-delays-beyond-2030-deadline/), CHA AB 869 guidance (calhospital.org/hcai-notice-details-information-on-ab-869-seismic-compliance-delay-provisions/), HCAI MCN/CMIR FAQs (hcai.ca.gov/affordability/ohca/assess-market-consolidation/mcn-cmir-faqs/), Hooper Lundy and Mintz AB 1415/CMIR analyses (hooperlundy.com/navigating-new-ohca-notice-requirements-effective-january-1/; mintz.com 2025-07-16 first-CMIR and 2026-06-04 proposed-regs alerts), california_regulatory_requirements.md on file.

---

# Appendix B — Method

Nine strategy archetypes developed by independent teams; each attacked by a financial-realism, market/competitive, and regulatory/execution panel; failures repaired or replaced across up to three rounds until five survived.

## Round log

| Round | Archetypes developed | Confirmed (cumulative) | Failed this round |
|---|---|---|---|
| 1 | 9 | 1 | Mothership & Fleet; SilverPass Health; The Glass Hospital — Redlands Surgical Destination; Redlands Unbound; TERRACINA — The Telehealth Company That Can Admit You; HomeTeam Health — The Corridor Premium Flip; Inland Independence Platform; The 5/50 Continuum |
| 2 | 5 | 2 | Mothership & Fleet 2.0 — The Ambulatory Platform Company, Re-Underwritten; SilverPass Health (Rebuilt); Glass Hospital 2.0 — Factory First, Glass Second; Terracina, Inverted — The Escalation Layer |
| 3 | 4 | 5 | Glass Hospital 3.0 — The Funded Factory (Earn the Glass) |

## Grounding

Grounded in the project data files (HCAI, CMS Care Compare, NPPES census of 188 independents, LEHD/ACS, CDC PLACES, DOL 5500, IRS 990).